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Abstract 
 
Activin beta E is a member of the TGF-beta family of growth and differentiation 
factors. It is closely related to the other mammalian activin subunits activin beta A, 
beta B and beta C. Like them, it is synthesized as a biologically inactive monomeric 
proform which forms homo- and heterodimers and is processed by endoproteases, 
producing the mature peptide. The mature homodimer (activin E), or heterodimers 
containing the beta E subunit (e.g. activin AE) are subsequently secreted by the cell. 
Activin beta E has been found to be predominantly expressed in the liver, but to be 
downregulated in hepatocellular carcinoma. Overexpression of the protein in liver 
cells inhibited DNA synthesis and increased apoptosis. Upon liver damage, expression 
of INHBE, the gene coding for activin beta E, was downregulated. The role of the 
protein in mammalian physiology remains unknown, as interaction partners of the 
protein have not been identified so far and knock-out mice did not show an abnormal 
phenotype in liver regeneration or development. 
In order to investigate the biological functions of activin beta E, we established 
mammalian and insect cell expression systems, producing various epitope tagged 
and untagged variants of the protein. While exogenous addition of the prospective 
signaling molecule did not significantly alter the proliferation of the liver cell lines 
HepG2 and Hep3B, the producer cell lines themselves showed strongly decreased 
proliferation and increased cell size. 
Treatment of the erythroleukemia cell line K562 with activin A, but not activin E, 
induced differentiation of the cells towards the erythroid lineage. Also cotreatment 
with activin A and activin E did not significantly alter the effects of activin A on the 
cells. 
Similarly, incubation of HepG2 cells with supernatants of activin beta A but not 
activin beta E expressing cells caused phosphorylation of smad 2. Cotreatment with 
low amounts of activin A and supernatants from activin beta E expressing cells did 
not noticeably affect the smad 2 phosphorylation due to activin A in comparison to 
mock supernatants. 
While effects on MAP kinase signaling and on other pathways activated by activin A 
remain to be elucidated, our results indicate that activin E does not signal via similar 
pathways as activin A, nor does it inhibit the action of its more famous relative at this 
level. 
 
Zusammenfassung 
 
 
Activin beta E gehört zur TGF-beta Familie von Wachstums- und 
Differenzierungsfaktoren. Wie seine nahen Verwandten in Säugetieren, Activin 
beta A, Activin beta B und Activin beta C, wird es als inaktive, monomerische, 
Proform synthetisiert. Diese kann in Folge Homo- und Heterodimere bilden. Ein 
Homodimer aus zwei beta E Untereinheiten wird Activin E, ein Heterodimer etwa aus 
einer beta E und einer beta A Untereinheit Activin AE genannt. Nach der 
Prozessierung durch Endoproteasen wird das mature Dimer sezerniert. 
In Säugetieren wird Activin beta E hauptsächlich in der Leber exprimiert. In 
Lebertumoren ist die Expression jedoch reduziert. Selbiges geschieht im Zuge der 
Leberregeneration nach einer Schädigung. Künstliche Überexpression führte zu einer 
Hemmung der DNA-Synthese und verminderter Zellproliferation. 
Die physiologische Funktion des Proteins ist jedoch großteils unbekannt, da bisher 
keine Interaktionspartner nachgewiesen werden konnten, und Knock-out Mäuse 
keine Veränderungen bezüglich Entwicklung oder Leberregeneration zeigten. 
Zur Ergründung der Rolle des Proteins in Säugetieren wurden von uns 
Expressionssysteme für epitopmarkiere Formen des Proteins etabliert. Behandlung 
der Leberzelllinien HepG2 und Hep3B mit Überständen von Activin beta E 
exprimierenden Zellen zeigte keine deutliche Beeinflussung des 
Wachstumsverhaltens der Zellen. Die überexprimierenden Zelllinien selbst jedoch 
wuchsen langsamer und hatten einen deutlich größeren Zelldurchmesser als 
Kontrolllinien. 
Die Leukäme-Zelllinie K562 reagierte mit Differenzierung auf die Zugabe von 
Activin A zum Medium, nicht jedoch auf die Zugabe von Activin E. Ebenso wenig 
hemmte Activin E die Wirkung von Activin A. 
Behandlung von HepG2 Zellen mit den Überständen von Activin beta A 
exprimierenden Zellen, nicht jedoch mit denen von Activin beta E exprimierenden 
Zellen, führte zur Phosphorylierung von Smad 2. Die gemeinsame Behandlung der 
HepG2 Zellen mit Activin A und Activin E führte zu keiner deutlichen Verminderung 
der durch Activin A hervorgerufenen Phosphorylierung im Vergleich zu Kontrollen. 
Obwohl die Effekte von Activin E auf andere Signalwege, welche durch Activin A 
aktiviert werden, noch nicht untersucht werden konnten, deuten unsere Ergebnisse 
darauf hin, dass Activin E deutlich anders wirkt als Activin A und dieses auch nicht in 
seiner Wirkung inhibiert. 
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1. Introduction 
 
Activin beta E is a member of the activin branch of the TGF-beta family of growth 
and differentiation factors (Schmierer & Hill, 2007) – for an overview see Figure 1. It 
was first described in the mouse by Fang et al. (Fang, Yin et al., 1996). This was 
followed by identification and cloning of the orthologue in rat (O'Bryan, Sebire et al., 
2000) and human (Hashimoto, Tsuchida et al., 2002). The human genome contains 
genes encoding for four different activin subunits called activin beta A (encoded by 
INHBA), activin beta B (INHBB), activin beta C (INHBC) and activin beta E (INHBE) 
(Deli, Kreidl et al., 2008). Activin beta D has so far been described in Xenopus laevis 
only (Oda, Nishimatsu et al., 1995). The name activin is derived from the original 
description of the founding member of this protein family as an inducer / enhancer of 
synthesis and secretion of Follicle-stimulating hormone (FSH) (Harrison, Wiater et al., 
2004). Later activins were reported to play a role in multiple other processes like 
development, erythroid differentiation, nerve cell survival, mesoderm induction in 
Xenopus, bone growth and induction of cell cycle arrest and apoptosis (Woodruff, 
1998). The function of activin beta E remains to be elucidated. The following sections 
will focus on the properties and functions of activins in humans. 
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Figure 1 relationships within the TGF-beta family; 
phylogenetic tree derived from protein alignments of TGF-beta signaling molecules in humans (black) 
and Drosophila melanogaster (grey); adapted from (Schmierer & Hill, 2007) 
 
1.1. Structure 
 
Activins are homo- or heterodimers of the four different subunits named above. A 
homodimer of two activin beta A subunits gives rise to activin A, a heterodimer of 
one beta A and one beta B subunits gives rise to activin AB. While activins AB and AC 
have been described under endogenous conditions in vivo (Evans, Muttukrishna et 
al., 1997; Mellor, Ball et al., 2003), activins BC, AE and CE have only been found in in 
vitro systems so far (Mellor, Cranfield et al., 2000; Vejda, Cranfield et al., 2002; 
Vejda, Erlach et al., 2003; Wada, Medina et al., 2005). Activin subunits are 
synthesized as pro-proteins of 350 to 426 aa (Deli, Kreidl et al., 2008). The protein is 
glycosylated in the prodomain region, but addition of the carbohydrate group seems 
to be dispensable for secretion. This is in contrast to the related inhibin alpha, a 
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member of the TGF-beta family and dimerization partner of activin subunits (see 
below) (Antenos, Stemler et al., 2007).  
Dimers are created by intermolecular disulphide bond formation between the sixth of 
nine conserved cysteines in the mature proteins. The other cysteines are involved in 
the formation of intramolecular disulphide bonds, creating the so-called cysteine 
knot, typical for members of the TGF-beta family. It is required for biological activity 
of the proteins (Mason, 1994).  
Following dimerization, the protein is cleaved by pro-protein convertases of the 
subtilisin/kexin family in ER and Golgi, producing a mature peptide chain of 115 to 
116 aa (see Figure 2). While the biologically active protein is secreted as a dimer of 
the mature peptides only, it has been suggested that the pro-region is required for 
correct folding, dimer formation and secretion (Gray & Mason, 1990). Unprocessed, 
dimeric activin A was found to be biologically inactive (Mason, Farnworth et al., 
1996). Monomers have been reported to retain some affinity for the receptors of 
dimeric activin A but do not cause activation (Husken-Hindi, Tsuchida et al., 1994). 
In addition to dimerization with another beta subunit, activin beta A and 
activin beta B can form heterodimers with inhibin alpha, giving rise to inhibin A or 
inhibin B, both inhibiting FSH release (Ying, 1987). It remains unknown if inhibin C 
exists, as there was evidence for the formation of a dimer between activin beta C 
and inhibin alpha in some (Ushiro, Hashimoto et al., 2006) but not in other 
experiments (Mellor, Cranfield et al., 2000). No data on this subject has been 
published for activin beta E. 
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Figure 2 structure and dimerization of activin beta E; 
activin beta E is synthesized into the ER as a pro-protein containing a glycosylation signal in its 
prodomain; it is able to dimerize with other subunits of the activin family via the formation of 
disulphide bridges and is then processed and secreted 
 
1.2. Expression 
 
While the genes coding for activin beta A and activin beta B, INHBA and INHBB, are 
almost ubiquitously expressed, mRNA from INHBC is only detected in the liver and 
(to a lesser degree) in a small number of other organs (Butler, Gold et al., 2005). 
INHBE is highly expressed in the liver only (Fang, Wang et al., 1997; Vejda, Cranfield 
et al., 2002), but has also been detected by RT-PCR in the rat lung (O'Bryan, Sebire 
et al., 2000) and at low levels in other tissues as well (Hashimoto, Tsuchida et al., 
2002; Vejda, Cranfield et al., 2002). The genes coding for activin beta C and beta E 
are closely linked and are thought to have arisen from tandem duplication of an 
ancestral gene (Fang, Wang et al., 1997). 
Expression of activin beta E mRNA was transiently upregulated following liver 
damage and downregulated in hepatocellular carcinoma (Grusch, Drucker et al., 
2006; Rodgarkia-Dara, Vejda et al., 2006). The latter observation has also been 
made for activin A which in contrast was found to be downregulated in response to 
liver damage (Deli, Kreidl et al., 2008). Additionally, INHBE expression was found 
and confirmed to be elevated in HepG2 cells as a consequence of phospholipidosis, a 
lipid storage disorder (Atienzar, Gerets et al., 2007; Sawada, Takami et al., 2005). 
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In the liver of the developing mouse, activin beta E expression could not be detected 
until the very late stages of embryonic development and peaked at birth (Lau, Kumar 
et al., 2000). 
Large scale analysis identified mutations in the INHBE gene to be significantly 
increased in breast cancer (Sjoblom, Jones et al., 2006). An evaluation of single 
nucleotide polymorphisms (SNPs) in genes coding for activins in testicular cancer 
showed a correlation for the risk of disease and mutations in INHBA but not in 
INHBB, INHBC or INHBE (Purdue, Graubard et al., 2008). 
Overexpression of the tumor suppressor RASSF1A stimulated expression of INHBE, 
while knock-down of endogenous RASSF1A in nasopharyngeal epithelial cells resulted 
in downregulation of INHBE (Chow, Lam et al., 2006).  
INHBE was also reported to be a target of hedgehog signaling (Katoh & Katoh, 
2008). 
Finally, in gene chip analysis, mRNA levels from INHBE were found to be altered in 
HepG2 in response to hypoxia (Fisher, Etages et al., 2005). 
 
1.3. Receptors 
 
Like other members of the TGF-beta family, activins are believed to signal via 
single-pass transmembrane receptors with an intracellular Ser–Thr kinase domain. 
This has been proven for activins A, B and AB. Activin A first binds to dimers of the 
type II receptors ActR-II (aka ACVR2) or ActR-IIB (aka ACVR2B), leading to the 
(preferential) recruitment and phosphorylation of dimers of the type I receptor 
ALK4 (aka ActR-IB / ACVR1B). While binding to the same type II receptors, activins B 
and AB preferentially recruit ALK7 (ACVR1C) as type I receptor (Deli, Kreidl et al., 
2008; Schmierer & Hill, 2007). Upon ligand binding, receptors are typically 
internalized (Dore, Yao et al., 2001). It has been questioned however, if this 
internalization is always necessary for signaling (Zhou, Scolavino et al., 2004). 
As a consequence of activation, receptor-regulated smads (R-smads) are recruited to 
the receptor complex and phosphorylated by the type I receptor. This process is 
supported by accessory proteins like SARA and the motor protein kinesin-1. 
Depending on the identity of this receptor, either smad 2 and smad 3 (ALK4, ALK5, 
ALK7) or smad 1, smad 5 and smad 8 (ALK1, ALK2, ALK3, ALK6) are recruited and 
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activated (Schmierer & Hill, 2007). For TGF-beta, it has been shown, that the ligand 
can recruit different type I receptors, activating different subsets of smads depending 
on the cell type (Lee, Ray et al., 2008). So far, activins have only been shown to 
signal through smad 2 and smad 3 (Harrison, Wiater et al., 2004). R-smads then 
form complexes with the common mediator smad 4 and translocate to the nucleus 
where, together with cofactors, they are directly involved in regulation of gene 
expression. Despite this narrowing down of the signals induced by several dozen 
different members of the TGF-beta family, to just a handful of R-smads, signaling is 
regulated and “personalized” by a large number of inhibitors and modulators (the 
most famous ones being the inhibitory smads 6 and 7) and the requirement of 
co-receptors for some, but not for other ligands (Schmierer & Hill, 2007). 
In addition, recent evidence suggests smad independent signaling of activin A via 
MAP kinases ERK 1/2 and p38 (Murase, Okahashi et al., 2001) as well as the 
phosphatidylinositol 3’-kinase (PI3K) / Akt pathway (Dupont, McNeilly et al., 2003). 
Rho and JNK were also found to be stimulated by activin A (Zhang, Deng et al., 
2005). 
Whether or not these mechanisms also apply to activins C, E or heterodimers of their 
subunits remains unknown. 
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Figure 3 receptor mediated signaling of TGF-beta family proteins via the smad pathway; 
binding of the ligand to either type I or type II receptors results in the recruitment of the opposite 
type of receptor and eventually phosphorylation of R-smads; these form complexes with the common 
mediator smad and translocate to the nucleus where they directly influence gene expression; adapted 
from (Schmierer & Hill, 2007) 
 
1.4. Biological functions 
 
Both activin A and B have wide-ranging functions in development and tissue 
homeostasis. Knock-out mice for activin beta A have severe craniofacial defects and 
die shortly after birth, while deletion of activin beta B results in defects of eyelid 
development and female reproduction. Cloning of activin beta B into the beta A locus 
can partially rescue the defects (Chang, Lau et al., 2001). Mice with deletions of 
activin beta C, beta E or both developed normally and showed no impairment of liver 
function or regeneration (see below) (Lau, Kumar et al., 2000). 
Activin A has been found to stimulate the growth of a variety of cells like fibroblasts, 
keratinocytes and osteoblasts (Chen, Lui et al., 2002) and is in some cases suspected 
to aid in carcinogenesis (Chen, Wang et al., 2006). In addition activin A and B were 
found to act as survival factors for neuronal cells (Kupershmidt, Amit et al., 2007). 
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On the vast majority of healthy epithelial cells and tumor cells however, activin A 
acts as a suppressor of proliferation (Risbridger, Schmitt et al., 2001). In 
hematopoiesis, activin A has been suggested as a negative regulator of 
lymphopoiesis and an inducer of erythropoiesis (Shav-Tal & Zipori, 2002). 
Finally, it has been proposed that effects of exogenous and endogenous activins 
differ. While some cell lines are immune to the antiproliferative action of activin A in 
the medium due to production of follistatin, endogenous activin A is able to act as an 
inhibitor of proliferation in these cells (Delbaere, Sidis et al., 1999).    
The biological functions of activin beta E remain largely unknown. Overexpression of 
activin beta E in the human hepatoma cell lines HepG2 and Hep3B, as well as in the 
murine hepatocyte cell line AML12 caused decreased proliferation and induced 
apoptosis (Vejda, Erlach et al., 2003; Wada, Medina et al., 2005). Transient 
overexpression of activin beta E in the mouse inhibited regenerative DNA synthesis 
(Chabicovsky, Herkner et al., 2003), while mice constitutively overexpressing the 
protein showed impaired growth of pancreatic exocrine cells (Hashimoto, Ushiro et 
al., 2006). 
One possible mode of action for activin beta E was described by (Chow, Lam et al., 
2006) who showed, that expression of Inhibitor of DNA binding 2 (Id2) is 
downregulated in response to overexpression of activin beta E. Id2 is a known target 
of TGF-beta and a potential oncogene (Lasorella, Uo et al., 2001). 
 
1.5. Antagonists 
 
Activin signaling is counteracted by a large variety of intra- and extracellular 
mechanisms. On the intracellular level, most widely known inhibition happens 
through the action of the inhibitory smads 6 and 7 (I-smads). In particular for 
smad 7, the antagonistic effect has been well documented (Lebrun, Takabe et al., 
1999). While the exact mechanism of action of I-smads remains unknown (Schmierer 
& Hill, 2007), it was shown that smad 7 interferes with the association of the 
receptor smads with the type I receptor ALK4 in case of activin A, by this preventing 
relaying of the signal to the nucleus (Lebrun, Takabe et al., 1999). 
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Inhibitory smads may also act by a variety of other mechanisms, like the recruitment 
of ubiquitin ligases (e.g. SMURF 1 and SMURF 2) or phosphatases (e.g. PP1) to the 
receptors (Schmierer & Hill, 2007). 
Further upstream, activin A signaling is regulated by membrane (bound) proteins. 
Cripto attaches to the outer membrane via a GPI-anchor and associates with the 
type I receptor ALK4, acting as a coreceptor for the TGF-beta family protein nodal. 
Additionally, together with activin A it may associate with type II receptors (ACVR2 
or ACVR2B), inhibiting the formation of functional signal complexes (Gray, Harrison 
et al., 2003). The protein lefty on the other hand has been shown to interact with 
cripto, preventing signaling by nodal, but allowing signaling by activin A (Cheng, 
Olale et al., 2004). Cripto has been shown to be overexpressed in several human 
malignancies. The protein BAMBI which was also found to be highly expressed in 
some tumors is a pseudoreceptor related to type I receptors, but without a kinase 
domain, binding to type II receptors and inhibiting signaling. ARIPS 1 and 2 were 
described to interact with the type II receptor and inhibit activin A signaling (Liu, 
Tsuchida et al., 2006). 
Extracellularly, activins (shown for activins A, B, AB and E (Hashimoto, Tsuchida et 
al., 2002)) and other TGF-beta family molecules are bound and antagonized by 
follistatin (Deli, Kreidl et al., 2008). The related protein FLRG acts in a similar manner 
(Tsuchida, Arai et al., 2000) and has been found to prevent the growth inhibitory 
actions of activin A in some tumor cells (Razanajaona, Joguet et al., 2007).  
Alpha 2-macroglobulin (Vaughan & Vale, 1993) as well as several other proteins have 
been described to specifically bind activins. It is not in all cases clear however, if this 
binding serves an antagonistic purpose (Harrison, Wiater et al., 2004). 
A completely different mode of regulation happens on the level of dimer formation. 
As mentioned above, the classic inhibitors of activin A and B, inhibins, have one of 
their two subunits in common with their counterparts, but employ a different 
dimerization partner (inhibin alpha). This allows them to bind to the same receptor, 
without causing a signal. The (competitive) formation of activin AC has been 
suggested as one mechanism by which activin A signaling is modulated (Mellor, Ball 
et al., 2003). If activin beta C and E play a similar role, and if beta E also participates 
in dimer formation with inhibin alpha remains to be elucidated (Phillips, 2000). Figure 
4 summarizes several modes of regulation of activin signaling. 
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Figure 4 regulation of the action of activins; 
activin signaling has been suggested to be regulated – among other means – by extracellular binding 
of the ligand, competitive receptor binding and reduction of the pool of available monomers for one 
activin by the formation of other activins containing the same subunit (Phillips, 2000) 
 
1.6. Aims 
 
The aim of this thesis was to elucidate potential functions and signaling mechanisms 
of the human activin beta E subunit. Central to this was the creation and 
characterization of expression systems for the study of this little recognized member 
of the TGF-beta family, as well as the establishment of appropriate in vitro assays for 
testing its role in signal transduction. While full characterization of the protein would 
clearly have been beyond the scope of a diploma thesis, setup of functional assays 
and preliminary results guiding the way for future experiments has been achieved. 
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2. Materials and Methods 
 
2.1. Cell lines and media 
 
All cell lines (see Table 1) were supplied by the cell culture unit of the Institute of 
Cancer Research except for CHO DHFR- cells which were supplied by Biopharm. All 
media used (see Table 2), except for MEM alpha and Insect Express were purchased 
from Sigma. MEM alpha was from Invitrogen, Insect Express was from PAA. Fetal 
bovine serum (FBS) and penicillin / streptomycin (P/S) were bought from PAA, 
hypoxanthine (HT) was from Invitrogen. 
 
Table 1 cell lines used in experiments 
cell line  medium 
CHO-DHFR- 
chinese hamster ovary cell line deficient for dihydrofolate 
reductase (DHFR) (Kingston, Kaufman et al., 2002) DMEM; 1 x HT* / MEM alpha; 1% P/S 
HCT116 human colonic carcinoma cell line (Brattain, Fine et al., 1981) MEME; 10% FBS; 1% P/S 
HEK293 
cell line derived from human embryo renal cortical cells 
(Graham, Smiley et al., 1977) DMEM; 10% FBS; 1% P/S 
Hep3B human hepatoma cell line (Knowles, Howe et al., 1980) RPMI; 10% FBS; 1% P/S 
HepG2 human hepatoma cell line (Knowles, Howe et al., 1980) MNP; 10% FBS; 1% P/S 
HT1080 
human fibrosarcoma cell line (Rasheed, Nelson-Rees et al., 
1974) M+N; 10% FBS; 1% P/S 
K562 
human myelogenous leukemia cell line (Lozzio & Lozzio, 
1979) RPMI; 10% FBS; 1% P/S 
MGC human glioblastoma cell line (Ponten & Macintyre, 1968) MEME; 10% FBS; 1% P/S 
Sf9 
ovarian cell line from Spodoptera frugiperda (Vaughn, 
Goodwin et al., 1977) Insect Express; 10% FBS; 1% P/S 
* before transfection with DHFR plasmid 
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Table 2 media used in cell culture 
DMEM Dulbecco's modified Eagle's medium 
RPMI Roswell Park Memorial Institute medium 
MEME Minimum essential medium Eagle 
MNP MEME; 1 mM sodium pyruvate (Sigma); 1% non-essential amino acids (PAA) 
M+N MEME; 1 mM sodium pyruvate 
MEM alpha Minimum essential medium (MEM) alpha modification; medium without 
(deoxy)ribonucleosides 
Insect Express insect cell medium 
 
2.2. Standard growth conditions 
 
All mammalian cells were grown in a humidified incubator (Forma Scientific) at 37°C; 
5% CO2. Insect cells were grown in closed bottles at 27°C (incubator: Napco). 
25 cm2 (with and without filter), 75 cm2 and 175 cm2 tissue culture flasks (T25, T75, 
T175 respectively) were bought from Greiner Bio-One and BD Falcon. 15cm tissue 
culture dishes were bought from Sarstedt, 6-well, 12-well and 24-well plates were 
bought from IWAKI and 96-well plates were from TPP. 
 
2.3. Splitting 
 
For splitting of adherent cells, medium was aspirated and cells were washed once 
with PBS (137 mM NaCl (Merck); 2.7 mM EDTA (Merck); 10 mM Na2HPO4 
(Merck) pH 7.4). Trypsin/EDTA (T/E; 0.1% Trypsin (Difco); 0.01% EDTA (Fluka)) 
was then added and the cells were incubated at 37°C for about 5 min. The cells were 
then resuspended in medium or in PBS using a pipette. The desired number of cells 
was then seeded in full medium (medium with serum). 
 
2.4. Freezing 
 
For freezing, cells were grown in T75 bottles in full medium (including selection 
marker for stably transfected cell lines) until they were almost completely confluent. 
Adherent cells were detached using T/E and resuspended in 6-8 mL of medium with 
10% serum and DMSO (Amresco) at a final concentration of 50 μL/mL. 1 mL each 
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was transferred to cryotubes (Greiner) and cooled down for at least 24 h in a 
styrofoam container placed at –80°C before being transferred to a liquid nitrogen 
tank for long term storage.  
 
2.5. Transfection 
 
Adherent mammalian cells were mainly transfected using either ExGen 500 
(Fermentas) or FuGENE 6 (Roche) according to the instructions of the 
manufacturers. 
In brief, for a T25 bottle, 6.25 μg of plasmid DNA (one or several plasmids) were 
diluted in 150 mM NaCl (500 μL total volume), mixed with 20.6 μL of ExGen and 
incubated for 10 min at RT. The mixture was then added to cells in logarithmic 
growth in full medium. Gene expression was assessed 24-48h following transfection. 
In case of FuGENE 6 (T25), 7.5 μL were diluted in 250 μL of serum free medium and 
incubated for 10 min at RT. 2.5 μg of plasmid DNA were added and the mixture was 
incubated for 15-45 min before being added to cells (full medium). 
Sf9 cells were transfected using FuGENE 6 or Cellfectin (Invitrogen). 
FuGENE was applied in a similar manner as for mammalian cells only that about 5 μg 
of bacmid DNA were used instead of 2.5 μg. 
For transfection with Cellfectin, 3 μg of bacmid DNA were diluted in a total of 200 μL 
serum free medium. 30 μL of Cellfectin were mixed with 170 μL of serum free 
medium which was mixed with the serum / DNA solution. The whole solution was 
incubated for 45 min at RT and then topped up to 2 mL with medium containing 
10% FBS. Old growth medium was removed from the cells to be transfected and the 
transfection mixture was added to the cells. The following day, a change of medium 
was performed. 
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2.6. Selection of stable transfectants 
 
For creation of stably expressing cell lines, the antibiotics neomycin / G418 and 
puromycin were used to select for cells that had integrated the plasmid coding for 
the gene of interest and a selection marker into their genome. To reduce the risk of 
the appearance of fake clones, in most cases a plasmid encoding for a bicistronic 
mRNA containing the gene of interest and a selection marker, separated by an 
internal ribosome entry site (IRES; (Gurtu, Yan et al., 1996)), was used. In case of 
CHO cells, the DHFR system (see 2.7) was used in addition.  
The day following transfection, cells were split 1:4 and either G418 or puromycin was 
added to the cells (see Table 3). About 48 h later, the medium was changed to 
remove dead cells. At the appearance of resistant clones (1 week following 
transfection), cells were re-seeded to facilitate growth. Gene expression was 
assessed by western blot or immunohistochemistry (IHC). 
Table 3 additives to media used for the selection of stable mammalian cell lines 
cell line G418 (PAA) puromycin (PAA) methotrexate (Sigma) 
CHO* 500 μg/mL 5 μg/mL 5 nM  
(starting concentration) 
HEK293 500 μg/mL 0.5 μg/mL - 
*(Asada, Honda et al., 2006; Kingston, Kaufman et al., 2002) 
 
2.7. Amplification of a gene of interest in stable cell lines 
 
To induce high expression of the gene of interest in stable cell lines, the 
dihydrofolate reductase expression system (Kingston, Kaufman et al., 2002) was 
used. In brief, CHO-DHFR- cells were co-transfected with the respective vector and a 
plasmid encoding for dihydrofolate reductase (DHFR). This particular cell line, 
deficient for DHFR, is not able to synthesize certain amino acids and purines if not 
artificially supplied with them through the medium. Growth in medium not containing 
nucleosides, like MEM alpha, results in selection for cells that have taken up and 
integrated into their genome, the gene coding for DHFR. Since two plasmids typically 
integrate into the genome at the same site (Chen & Chasin, 1998; Colbere-Garapin, 
Ryhiner et al., 1986), it is likely, that the plasmid coding for the gene of interest, 
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which is supplied in a 5:1 ratio, co-integrates with the DHFR gene. Following 
transfection, CHO cells were grown in MEM alpha, containing either G418 or 
puromycin for selection (see above). Once a cell line had been established that grew 
stably under these conditions and expressed the gene of interest, methotrexate 
(MTX) (starting concentration 5 nM; see Table 3) was added to the medium. MTX is 
a competitive inhibitor of DHFR. To adapt to the presence of this inhibitor, cells often 
react by a gene amplification of the DHFR gene (Banerjee, Ercikan-Abali et al., 1995) 
which often leads to co-amplification of the gene of interest, integrated nearby. As 
soon as cells had adapted to these conditions and resumed growth at a normal rate, 
the concentration of MTX was raised again by a factor of 4. The whole procedure 
was repeated over the course of several months. 
 
2.8. Immunohistochemistry 
 
For immunohistochemistry (IHC), cells were seeded in 12-well plates containing 
coverslips (Paul Marienfeld GmbH) 24 h (no further treatment necessary) or 48h-72 h 
(if cells had to be transfected) prior to staining at a density that resulted in about 
75% confluency on the day of staining. 
Because of the better results, in all late experiments, cells were fixed with 
paraformaldehyde (PFA; Fuka) rather than methanol (MeOH; Merck) – see Figure 5. 
A 37% stock solution of PFA was prepared by dissolving 1.85 g PFA in 3.5 mL water 
with 10 μL 10 M KOH at 65°C. The stock solution was stored at –20°C. On the day of 
staining, the medium was aspirated from the wells and the cells were washed twice 
for 5 min with cold PBS. PBS was removed and the cells were fixed either with PFA 
(3.7% in PBS) for 10 min at RT or with MeOH for 3 min at –20°C. The fixative was 
aspirated and cells were washed 3 times for 5 min with PBS. Cells were blocked with 
PBS, 2% milk for 1 h at RT on a shaker. In case of PFA fixation, 0.5% Triton X-100 
(Serva) was added to the blocking solution to permeabilize the cells. Cells were 
incubated in primary antibody (for list of antibodies used, see Table 4) diluted in 
blocking solution by putting the coverslip upside-down in the antibody solution and 
incubating in a wet chamber at 37°C for 1 h. Coverslips were then washed several 
times in PBS and incubated with secondary antibody in a similar manner. Following 
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final washes, positive cells were stained by incubating coverslips with DAB solution 
(DAKO). 
 
Figure 5 comparison of paraformaldehyde (left) and methanol (right) fixation for IHC; 
CHO cells, transfected with vector containing an expression cassette for HA-tagged TGF-alpha were 
fixed either with paraformaldehyde or methanol and stained with rat-anti-HA (1:50) and 
goat-anti-rat-HRP (Pierce; 1:200); red arrows mark examples of stained cells 
 
Table 4 antibodies used in IHC 
mntibody dilution used manufacturer 
rat-anti-HA 1:50 Roche; 11867423001 
goat-anti-rat-HRP 1:200 Pierce; 31470 
rabbit-anti-rat-HRP 1:50 Dako; P0450 
 
2.9. Cell counting 
 
Cells were counted using either a Neubauer chamber (Phelan, 2007) (Paul Marienfeld 
GmbH) or a Casy cell counter (Schärfe). 
 
2.10. Benzidine staining of K562 cells 
 
K562 cells were seeded in 96-well plates at a density of 10 000 cells per well in 
RPMI.  
As a positive control for the induction of differentiation towards the erythroid lineage, 
hemin (Ueki, Zhang et al., 2004) (Sigma; final concentration in medium: 50 μM) and 
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activin A (Wang, Huang et al., 2008) (R&D; final concentration: 25 ng/mL) were 
added. To determine the effect of activin E, supernatants from cells producing 
different variants of the protein were added to the cells, alone or in combination with 
activin A. Experiments were done in triplicates. It was found that the presence of 
serum in the medium significantly improved the viability of the cells making counting 
of positive cells significantly easier. Cells were incubated without media change for 
3-5 days before staining cells for hemoglobin with 3,3’-dimethoxybenzidine (Lebrun & 
Vale, 1997). Medium was aspirated and cells were resuspended in 100 μL PBS. 40 μL 
were transferred to a new well, followed by centrifugation at 1000 g for 5 min. 10 μL 
benzidine staining solution (1.5 mg 3,3’-dimethoxybenzidine (Dr. Ehrenstorfer 
GmbH); 1 mL H2O; 25 μL 30% H2O2 (Sigma) 50 μL glacial acetic acid (Merck)) were 
added directly before evaluation by light microscopy. Digital images were taken and 
the total cell number was determined automatically using Image J software and the 
Nucleus Counter plug-in (http://rsb.info.nih.gov/ij/). Positive cells (see Figure 6) 
were counted by hand using Image J and the Cell Counter plug-in. 
 
 
Figure 6 K562 cells stained with benzidine for hemoglobin; 
red arrows mark examples of positive cells 
 
2.11. Determining DNA concentration 
 
Concentration of purified linear or circular DNA was determined using a 
NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific). 
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2.12. Restriction digest 
 
Restriction digest was performed (where possible) in 10 μL total volume. For larger 
volumes, amounts were increased accordingly. To determine the identity of a 
plasmid, about 200 ng of DNA were digested with 5 units restriction enzyme 
(Fermentas, unless stated otherwise) in respective buffer for 2-3 h at the suggested 
incubation temperature (typically 37°C). For preparative digestion 1-3 μg of plasmid 
were digested with 10-20 units of restriction enzyme overnight (o/n).  
For double digests, buffers and conditions (excess of one enzyme over the other) 
were used as suggested by Fermentas. 
At several occasions, Fermentas FastDigest buffer was used (for FastDigest and 
regular enzymes) and incubation time was reduced to 15-30 min. In general, 
conventional digestion seemed to yield better results (data not shown). 
 
2.13. Dephosphorylation of linear DNA fragments 
 
To prevent recircularization of a vector backbone without the integration of an insert 
(where desired), linear DNA was dephosphorylated with calf intestinal alkaline 
phosphatase (CIAP; Fermentas). 1 μg of DNA was incubated with 1 unit of CIAP 
either in the buffer supplied with the phosphatase or any restriction enzyme buffer 
for 30 min at 37°C. Incubation temperature was raised to 50°C and CIAP was added 
again at 1 unit per μg of DNA. Incubation was continued for another 30 min before 
the reaction was terminated by increasing the temperature to 85°C for 15 min or 
purifying the DNA by agarose gel electrophoresis. 
 
2.14. Phosphorylation of linear DNA fragments 
 
For direct integration of PCR products into a blunt end vector backbone, the PCR 
product generated by Pfu DNA Polymerase was phosphorylated using 
T4 polynucleotide kinase (PNK; Fermentas). 50 μL PCR reaction were mixed with 
5 μL PNK (10 units/μL), 16 μL PEG 6 000 (Fermentas), 9 μL 10 x PNK-Buffer A and 
9 μL rATP (10 mM; Promega). The reaction was incubated at 37°C for 1 h and 
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stopped either by increasing the temperature to 75°C for 10 min or purification of 
the DNA fragment by gel electrophoresis. 
 
2.15. Gel electrophoresis 
 
DNA fragments of the typical size of 1-3 kilobases (kb) were separated on gels 
consisting of 1% (w/v) agarose (Biozyme) in 0.5 x TBE buffer (5.4 g/L Tris (Fluka) 
2.75 g/L boric acid (Sigma); 1 mM EDTA). Samples were mixed with 6 x loading 
buffer (333 μL/mL 6 x loading dye (Fermentas); 250 μL/mL 80% glycerol (Merck); 
66.5 μL/mL 0.5 M EDTA; 0.5 μL/mL 10 000 x Vistra-Green (GE Healthcare)) and 
loaded onto the gel. As a marker 2 μL GeneRuler 1 kb DNA Ladder (Fermentas), 
mixed with appropriate amounts of water and loading buffer were used. 0.5 x TBE 
was used as a running buffer and the gel was run at a constant voltage of 50 V for 
10 min, followed by 160 V for 30 min (power supply: Bio-Rad).  
For smaller fragments, 2% gels (marker: GeneRuler 100 bp Plus DNA ladder 
(Fermentas)), and for larger fragments 0.5% gels were used. 
Bands were visualized using a FluorImager 595 Scanner from Molecular Dynamics. 
 
2.16. Ethanol precipitation 
 
Precipitation of DNA (e.g. for sequential digest using different buffers) was 
performed by mixing DNA solution with 3 volumes (V) 100% EtOH (Merck) and 
1/10 V 3 M Sodium Acetate pH 5.2 (Merck) and incubating the mixture at –20°C for 
at least 30 min. This was followed by centrifugation at 20 800 g; 4°C for 15 min 
(Eppendorf) and aspiration of the supernatant. The pellet was then washed with 
500 μL cold 70% EtOH and again centrifuged at 20 800 g; 4°C for 5 min. 
Supernatant was removed and the pellet was left to air dry for about 15 min. The 
pellet was then resuspended in the desired volume of nuclease free water or TE 
buffer pH 8 (100 mM Tris; 10 mM EDTA). 
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2.17. Gel elution and DNA purification of PCR products 
 
Both procedures were performed using the Wizard SV Gel and PCR Clean-Up System 
(Promega) according to the instructions of the manufacturer. Gel slices containing 
the bands of interest were cut from the gel with a scalpel and weighed. 
1 μL Membrane Binding Solution was added per 1 mg of gel slice. The mixture was 
incubated at 60°C and occasionally vortexed until dissolved. PCR reaction was mixed 
directly with an equal amount of Membrane Binding Solution. The solution was then 
transferred to an SV Minicolumn which had been inserted into a collection tube and 
incubated at RT for 1 min. The assembly was centrifuged at 16 100 g (Eppendorf) 
and the flow through was discarded. 700 μL Membrane Wash Solution were added to 
the minicolumn and centrifugation was repeated for 1min. Flowthrough was 
discarded and another 500 μL wash solution were added, followed by centrifugation 
for 5 min. DNA was eluted by adding 30 μL of water to the minicolumn, incubating 
for 1 min and centrifugation into a fresh Eppendorf tube for 1 min. 
 
2.18. DNA ligation 
 
For the ligation of an insert into a vector backbone, 100 ng of vector backbone were 
mixed with 3 times and 5 times molar excess of insert and 5 to 10 Weiss units 
T4 DNA ligase (Fermentas). In most cases Rapid Ligation Buffer (Fermentas) was 
used and reaction was incubated for 15-30 min at room temperature (RT). It was 
later found that the use of regular ligation buffer and incubating the reaction at RT 
o/n seemingly yielded better results. 
 
2.19. Preparation of competent E. coli 
 
E. coli of the strains JM109 and XL1-Blue were made competent and stored for 
further use as described by Inoue et al. (Inoue, Nojima et al., 1990) with slight 
modifications. 5 mL SOB (20 g/L tryptone (Fluka); 5 g/L yeast extract (Oxoid); 
0.5 g/L NaCl) were inoculated with either JM109 or XL1-Blue from a glycerol stock. 
The suspension was incubated on a shaker at 37°C o/n. The next day, 196 mL SOB 
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where mixed with 4 mL of the overnight culture and incubated on a shaker at 37°C 
until the OD600 had reached 0.55 (determined with NanoDrop spectrophotometer). 
Cells were then pelleted in a Sorvall RC5C centrifuge at 2 500 g and 4°C for 10 min. 
Supernatant was discarded completely and cells were resuspended in ice-cold Inoue 
Transformation Buffer (55 mM MnCl2.4H2O (Merck); 15 mM CaCl2.4H2O (Merck); 
250 mM KCl (Merck), 10 mM PIPES (Fluka) (stock: 0.5 M; pH 6.7)). Cells were again 
harvested by centrifugation at 2 500 g 4°C for 10 min. Supernatant was removed 
completely and cells were resuspended in 20 mL of ice-cold Inoue buffer. 
1.5 mL DMSO were added, the cell suspension was dispensed into 300 μL aliquots in 
pre-chilled 1.5 mL Eppendorf tubes and shock frozen with liquid nitrogen. Competent 
bacteria where then stored at -80°C until use. 
 
2.20. Transformation of E. Coli 
 
Competent E. Coli were thawed on ice. 100 μL bacterial cell suspension were mixed 
with 50% of ligation mix (typically 5–10 μL) and incubated on ice for 20 min. The 
bacteria where then heat-shocked at 42°C for 1-1.5 min. This was followed by 
addition of 1 mL of cold SOC medium (SOB; 20 mM glucose (Merck)) and incubation 
at 37°C; 350 rpm in a heat block for about 1 h. Finally, bacteria were plated on 
LB agar plates (20 g/L LB Broth (Sigma); 15 g/L agar (Fluka); petri dishes: Greiner) 
containing the appropriate antibiotic for selection (see Table 5) and incubated at 
37°C o/n in a humidified incubator (Heraeus). 
 
Table 5 Additives to media used for selection of bacteria 
antibiotic final concentration in growth medium 
ampicillin (Roche) 50 μg/mL 
kanamycin (Fluka) 50 μg/mL 
gentamicin (Sigma) 7 μg/mL 
X-gal (Fluka) 100 μg/mL 
tetracycline (Sigma) 10 μg/mL 
IPTG 40 μg/mL 
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2.21. Overnight culture and miniprep (boiling lysis) 
 
To identify bacteria containing the desired plasmid, colonies were picked from 
LB agar plates and grown in 3 mL LB medium containing the appropriate antibiotic 
for selection (see Table 5) in vented tubes (Falcon) at 37°C; 200 rpm in a shaker 
(GFL) o/n. The next day, 1 mL cell suspension was transferred to an Eppendorf tube 
and cells were harvested at 16 100 g for 1 min. Supernatant was removed and cells 
were resuspended in 700 μL STET buffer (50 mM Tris; 50 mM EDTA; 20 g/L sucrose 
(USB); 5% Triton X-100). 13 μL lysozyme (10 mg/mL; Sigma) were added and the 
reaction was mixed and then heated to 100°C for 1.5 min. This was followed by 
centrifugation at 16 100 g for 10 min. The pellet was removed with a toothpick that 
had been tipped into RNAse A (10 mg/mL; Sigma) and 700 μL isopropanol (Merck) 
were added. The mixture was incubated at –20°C for 15 min and precipitated DNA 
was pelleted at 20 800 g for 15 min at 4°C. Supernatant was removed, the pellet 
was washed in 500 μL 70% EtOH and pelleted again at 20 800 g for 5 min at 4°C. 
Supernatant was completely removed and the pellet was dried at 37°C. It was then 
resuspended in 30 μL TE buffer. 
 
2.22. Glycerol stocks 
 
Glycerol stocks were created by mixing 700 μL overnight bacterial culture with 
300 μL 80% glycerol. Stocks were stored at –80°C. 
 
2.23. Miniprep 
 
Plasmid minipreps were done using the Wizard Plus SV Miniprep DNA Purification 
System (Promega). 20 mL of bacterial overnight culture were centrifuged for 1 min 
at 15 000 g. Supernatant was removed and cells were resuspended in 
250 μL Cell Resuspension Solution. 250 μL Cell Lysis Solution were added and the 
reaction was incubated for 3 min at RT. 10 μL Alkaline Protease Solution were then 
added and incubation was repeated for 5 min at RT. This step was succeeded by the 
adding of 350 μL Neutralization Solution and centrifugation at 16 100 g for 10 min. 
Supernatant was transferred to a Spin Column which had been inserted into a 
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Collection Tube and centrifuged for 1 min at 16 100 g. Flowthrough was discarded 
and 750 μL Column Wash Solution were added to the column. After centrifugation 
(1 min 16 100 g), flowthrough was discarded again and another 250 μL of fresh 
Wash Solution were added to the column and passed through by another step of 
centrifugation for 2 min. DNA was eluted by adding 50 μL of nuclease free water to 
the column, incubation for 2 min and centrifugation into an Eppendorf tube 
(16 100 g; 1 min). 
  
2.24. Midiprep 
 
Plasmid midipreps were performed using the PureYield Plasmid Midiprep System 
(Promega). 
100 mL of bacterial overnight culture were harvested by centrifugation at 15 000 g 
for 1 min. The cell pellet was resuspended in 6 mL of Cell Resuspension Solution and 
lysed by addition of 6 mL Cell Lysis Solution followed by incubation at RT for 3 min. 
10 mL Neutralization Solution were then added and the reaction was incubated for 
another 3 min. The lysate was pre-cleared by centrifugation at 15 000 g for 10 min. 
The supernatant was transferred to the Clearing Column which had been inserted 
into the Binding Column, attached to a vacuum manifold (Promega). Vacuum was 
applied (pump: Welch) until all liquid had passed through both columns. The 
Clearing Column was then discarded and 5 mL of Endotoxin Removal Wash were 
passed through the Binding Column. Next 20 mL of Column Wash Solution were 
passed through the column. Vacuum was continued for 30-60 sec following the pass 
through of all liquid. Remaining liquid was removed from the column by drying the 
drain with a paper towel. 600 μL water were used to elute DNA from the column by 
incubating it for 5 min and collecting the DNA solution with the help of an 
Eluator Vacuum Elution Device (Promega). 
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2.25. PCR 
 
PCR reactions were carried out using either a Robocycler Gradient 40 (Stratagene) or 
a MyCycler (with gradient upgrade; Bio-Rad) PCR machine. Analytical PCR was 
performed using GoTaq DNA polymerase (Promega) while for preparative PCR 
Pfu DNA Polymerase (Fermentas) was used. See Table 6 for reaction mixes. Primers 
were bought from Invitrogen and Eurogentec, see Table 10 for list of primers used. 
Table 6 general reaction mixes for PCR 
analytical PCR preparative PCR 
17.375 μL nuclease free water (Fermentas) 40.5 μL nuclease free water (Fermentas) 
5 μL 5X Colorless GoTaq Reaction Buffer (Promega) 5 μL 10x Pfu buffer with MgSO4 (Fermentas) 
0.5 μL dNTPs (10mM; Fermentas) 1 μL dNTPs (10mM; Fermentas) 
0.5 μL upstream primer (20 μM) 1 μL upstream primer (20 μM) 
0.5 μL downstream primer (20 μM) 1 μL downstream primer (20 μM) 
0.125 μL GoTaq DNA polymerase (5 units / μL) 0.5 μL Pfu DNA polymerase (2.5 units/μL) 
1 μL template DNA 1 μL template DNA 
when the Robocycler Gradient 40 PCR machine was used, 2 drops of mineral oil (Sigma) were put on 
top of the reaction mixes prior to the start of PCR 
 
 
2.26. Quantitative real-time PCR (QPCR) 
 
Quantitative real-time PCR (QPCR) was used to determine the amount of viral DNA in 
supernatants of baculovirus infected Sf9 cells (see 3.3.1) and thereby determine the 
virus titer (Lo & Chao, 2004). 
The Applied Biosystems 7500 Fast Real-Time PCR System and the 
Fast SYBR Green Master Mix (Applied Biosystems; (Morrison, Weis et al., 1998; 
Schneeberger, Speiser et al., 1995) for a recent review see (Mackay, Arden et al., 
2002)) were used to amplify and detect the PCR product. 
 
For one QPCR reaction, 5 μL of isolated viral DNA (see 2.28) were mixed with 6 μL of 
2 x SYBR Green Master Mix and 0.5 μL of each of the two primers (10 μM). For 
standard determination of Ct values for baculoviral sample DNA, primers 
baculo_QPCR_for (5’-CCCGTAACGGACCTCGTACTT-3’) and baculo_QPCR_rev (5’-
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TTATCGAGATTTATTTGCATACAACAAG-3’) were used. Primer sequences were taken 
from (Lo & Chao, 2004). 
The reaction was pipetted into 0.1 mL MicroAmp Fast Optical 96-well Reaction Plates 
(Applied Biosystems) and sealed with MicroAmp Optical Adhesive Film (Applied 
Biosystems). For each sample, QPCR was performed in duplicates, 
nuclease free water (Promega) was used as a negative control (no template control; 
NTC). QPCR was run in Fast 7500 Mode (see Table 7 for parameters), analysis was 
performed using 7500 Fast System SDS Software (Applied Biosystems). 
Table 7 cycling parameters for QPCR 
thermal cycler profile         
stage repetitions temperature time ramp rate 
1 1 95.0°C 00:30 Auto 
2 45 95.0°C 00:03 Auto 
    60.0°C 00:30 Auto 
 
2.27. Generation of baculoviruses 
 
The Bac-To-Bac Baculovirus Expression System (Invitrogen) was used to create 
recombinant baculoviruses for the expression of a gene of interest in both Sf9 insect 
cells (Luckow, 1993) and – with modifications - mammalian cells (Lackner, Genta et 
al., 2008). 
The gene of interest was cloned into the multiple cloning site (MCS) of the pFastBac 
transfer plasmid containing the insect cell specific polyhedrin promoter (PPH; (Smith, 
Summers et al., 1983)). Alternatively, a modified version of the vector (pFIP) 
containing the cytomegalovirus immediate early gene promoter / enhancer (CMV; 
(Lackner, Genta et al., 2008)) was used. The purified plasmid (see 2.21) was then 
used to transform the E. coli strain DH10 Bac as described in 2.20 but with 
incubation at 37°C for 4-5 h before plating bacteria on LB agar plates containing 
kanamycin, tetracycline, gentamicin, X-gal and IPTG (see Table 5). Following 
incubation for 48 h at 37°C, large white colonies were subjected to PCR analysis to 
test for successful integration of the gene of interest into the bacmid. For this, a 
small amount of cells was transferred directly into the master mix (see 2.25) with a 
pipette tip. LB medium containing kanamycin and gentamicin was inoculated with 
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cells from colonies containing the gene of interest and incubated overnight at 37°C. 
The next day, the overnight cultures were used for the creation of glycerol stocks 
and miniprep of bacmids. 
Bacteria were harvested from 1.5 mL of cell suspension by centrifugation (16 100 g; 
1 min) and resuspended in 0.3 mL cold solution 1 (15 mM Tris-HCl pH 8; 
10 mM EDTA; 100 μg/mL RNase A). 0.3 mL solution 2 (0.2 N NaOH; 1% SDS) were 
added and the reaction was incubated for 5 min at RT following gentle mixing. Next 
0.3 mL of 3 M potassium acetate pH 5.5 were added and the mixture was placed on 
ice for 5-10 min. This was followed by centrifugation at 16 100 g for 10 min and 
transfer of the supernatant to an Eppendorf tube containing 0.8 mL isopropanol. The 
reaction was again placed on ice for 5-10 min and then centrifuged at RT for 15 min 
at 16 100 g. Supernatant was removed and the pellet was washed with 500 μL 70% 
EtOH. Following centrifugation at 16 100 g for 5 min, supernatant was removed and 
the pellet left to dry for a few minutes before being carefully resuspended (without 
pipetting or vortexing) in 40 μL TE pH 8. The bacmid DNA solution was stored at 
4°C. 
Sf9 cells growing in a T25 flask (5 mL medium) were then transfected with bacmid 
DNA as described under 2.5.  
Five days to one week following transfection, cell supernatants were harvested from 
Sf9 cells and cleared by centrifugation at 1 000 g for 3 min. 50% of this P1 stock 
were then used to infect a T75 bottle (10 mL medium) almost confluent with Sf9 
cells. Another week later supernatant was harvested in a similar manner as before 
and viral DNA isolated for determination of virus titer from this P2 stock. When 
necessary, amplification was continued until a virus stock with a suitable 
concentration of viral particles (1 x 107 - 1 x 109 Pfu1/mL) was reached. Virus stocks 
were stored at 4°C. 
 
 
 
 
 
                                                 
1 plaque forming units 
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2.28. Isolation of baculoviral DNA from cell supernatants 
 
Baculovirus DNA was isolated from Sf9 cell supernatant using the 
High Pure Viral Nucleic Acid Kit (Roche) according to the protocol suggested by the 
manufacturer. 
In brief, 200 μL of cell supernatant (containing FBS), precleared by centrifugation at 
1 000 g for 1 min, were mixed with 200 μL Working Solution 
(200 μL Binding Solution supplemented with 4 μL carrier RNA), freshly prepared for 
each experiment. 50 μL Proteinase K were added and the reaction was incubated at 
72°C for 10 min following mixing. Next, 100 μL Binding Solution were added and the 
reaction was transferred to a High Filter Tube, inserted into a Collection Tube. The 
solution was passed through the column by centrifugation at 8 000 g for 1 min. 
Supernatant was discarded and 500 μL Inhibitor Removal Buffer were added to the 
column and passed through by centrifugation. Twice, 450 μL Wash Buffer were 
added to the column and passed through in a similar manner. Residual Wash Buffer 
was removed by centrifugation at maximum speed (16 100 g) for 1 min. The viral 
DNA was eluted into a 1.5 mL Eppendorf tube with 50 μL Elution Buffer and 
centrifugation at 8 000 g for 1 min. 
 
2.29. Determination of virus titer 
 
QPCR was used to determine the amount of viral particles in the medium / virus titer 
(Pfu/mL) as described by Lo et al. (Lo & Chao, 2004). A viral stock of known titer 
was used to correlate Ct-values to Pfu/mL (3.3). 
Virus titer was determined from Ct-values of samples obtained by QPCR (see 2.26) 
with the following formulas: 
 
Primer pair baculo_QPCR_for and baculo_QPCR_rev: 
 
⎟⎠
⎞⎜⎝
⎛ −
−
=
4332.1
294.35Ct
ec  
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Primer pair CMV_QPCR_for and CMV_QPCR_rev: 
 
⎟⎠
⎞⎜⎝
⎛ −
−
=
6138.1
538.38Ct
ec  
 
c…virus titer in Pfu/mL 
 
2.30. Infection of mammalian cells with baculovirus 
 
Mammalian cells were infected by incubating them with a suitable amount of viral 
particles. Typically a multiplicity of infection (MOI) of 500-1000 (500 viral particles 
per mammalian cell) was used. The equivalent amount of virus stock was added 
directly to the medium of mammalian cells growing at about 75% confluency. About 
24 h later, medium was removed, cells were washed several times with PBS and new 
growth medium was added. Gene expression was assessed 24-72 h post 
transfection. 
 
2.31. Creation of conditioned medium 
 
For the creation of medium containing secreted proteins, cells were grown to 
75-100% confluency. Regular growth medium containing serum was removed from 
the cells and they were washed 2 x with PBS. In case of proteins artificially 
expressed in cells, this procedure was performed 24-48 h post transfection. A 
minimal amount of medium (2 mL in case of a T25 bottle) with or without serum was 
added and cells were incubated for 48 h. Medium was then harvested and cleared by 
centrifugation for 3 min at 1 500 rpm.  
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2.32. Precipitation of protein from cell supernatants and 
preparation for gel electrophoresis 
 
Serum free cell supernatant was transferred to a SS34 centrifugation tube and 
4 volumes of 100% EtOH were added. The solution was incubated at –20°C o/n. The 
next day precipitate was harvested by centrifugation at 4°C for 10 min at 15 000 g. 
Supernatant was removed, and the precipitate was washed in cold 70% EtOH and 
pelleted again at 16 100 g for 5 min. Supernatant was removed completely and the 
pellet was briefly left to dry. It was then resolubilized in a minimal volume (typically 
25 μL for the precipitate from a T25 bottle) of sample buffer (7.5 M urea (Merck); 
1.5 M thiourea (Sigma); 4% CHAPS (Merck); 0.05% SDS (Fluka)). Insoluble 
precipitate was removed by centrifugation at 16 100 g for 5 min. Finally 6 μL 
5 x SDS-PAGE loading buffer (10% SDS; 60% glycerol; 300 mM Tris-HCl pH 6.8; 
7% 2-mercaptoethanol (Aldrich); 0.025% bromophenolblue (Koch-Light 
Laboratories)) were added and the mixture was loaded onto the gel without prior 
heating to prevent carbamylation of the proteins in the sample (McCarthy, Hopwood 
et al., 2003). 
 
2.33. Cell lysis and determination of protein concentration 
 
To collect non-secreted protein from cells for SDS-PAGE and western blot analysis, 
around 500 000 cells growing in a 6-well were harvested by removing growth 
medium and scraping them (Cornig) into cold PBS. Cells were pelleted by 
centrifugation at 1 000 g for 2 min. All successive steps were done on ice. 
Supernatant was removed and cells were lysed by adding 
Phospho-EGF-Receptor Lysis Buffer (1 mM EDTA, 150 mM NaCl, 0.5 mM Na3VO4 
(Sigma), 1.5 mM MgCl2 (Fluka), 10% Glycerol, 50 mM HEPES (USB), 10 mM NaF 
(Sigma), 1% Triton X-100) and pipetting up and down as well as passing the cell 
through a thin syringe or sonification 3 x for 1 min (Bandelin). Insoluble components 
were then removed by centrifugation at 4°C and 20 800 g for 10 min. Supernatant 
was subjected to Bradford assay (Bio-Rad Protein Assay ) to determine the protein 
concentration (Simonian & Smith, 2006). Bio-Rad Protein Assay was diluted 1:5 with 
Materials and Methods  30 
water and 199 μL of this solution for each of the samples to be measured and 
6 x 198 μL for the creation of a standard curve were added to separate wells of a 
PS microplate 96-well (Greiner). Each of the wells for the standard curve received 
1 μL of lysis buffer and an appropriate amount of a solution of BSA in water 
(0.1 μg/μL and 1 μg/μL) at different concentrations (see Figure 7 for an example of a 
standard curve). Each of the wells for the sample received 1 μL of cell lysate which 
had been diluted 1:3 in lysis buffer. Contents of the wells were mixed by pipetting 
and incubated at RT for 5 min. Absorption at 562 nm was determined using a 
SynergyHT plate reader and Gen5 software (both BioTEK). The formula obtained 
from measurement of the standard curve was used to calculate the protein 
concentration in the samples. 
 
 
  
protein concentration of standard 
(μg/μL) abs at 562 nm abs - abs(blank)
blank 0 0.294 0.000 
standard 1 0.1 0.322 0.028 
standard 2 0.3 0.325 0.031 
standard 3 0.5 0.377 0.083 
standard 4 1 0.451 0.157 
standard 5 2 0.554 0.260 
abs…absorption 
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Figure 7 example of a standard curve for the determination of protein concentration by 
Bradford assay 
2.34. Pulldown using anti-HA-agarose beads 
 
To precipitate HA tagged protein from conditioned medium or cell lysate, a suitable 
amount (supernatant from at least one T25 bottle, cell lysate from at least one T75 
bottle) was incubated with 50-100 μL (50% slurry) of Anti-HA Affinity Matrix (Roche) 
on a rotary shaker at 4°C o/n. The next day, beads were harvested by centrifugation 
at 1 500 g for 1 min and washed 5 x with 1 mL TBS 0.05% Tween 20; 0.1 mM EDTA. 
For elution of bound peptide, beads were incubated with 1 bed volume (BV) of 
HA peptide (Sigma) at 1 mg/mL in TBS 0.05% Tween 20; 0.1 mM EDTA for 15 min 
at 37°C. Alternatively, 100 mM glycine pH 2 was used in a similar manner or beads 
were boiled in 2 x SDS-PAGE loading buffer without reducing agents (e.g. 
2-mercaptoethanol). 
 
2.35. Polyacrylamide gel electrophoresis and western blot 
 
For detection of a protein of interest in cell lysate or supernatant, samples were 
subjected to SDS-PAGE (Gallagher, 2007) and western blot (Gallagher, Winston et 
al., 2008). The Mini Protean 3 system (Bio-Rad) was used for gel electrophoresis and 
transfer of protein to a PVDF membrane (Hypond-P; GE Healthcare) for 
immunodetection. Denaturing, discontinuous polyacrylamide gels with gel densities 
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of the separation between 7.5 and 15% were typically used. Occasionally PAGEr Gold 
Precast Gels 4-20% (Lonza) were used. The separation gel was cast and topped with 
isopropanol. Following polymerization (15-30 min), isopropanol was rinsed off with 
water which was removed with filter paper (Schleicher&Schuell). The stacking gel 
was then cast on top of the separating gel (for gel recipes see Table 8). Prior to 
loading, the gel pockets were cleaned with SDS running buffer (25 mM Tris; 
192 mM glycine; 0.1% SDS) which was also used as running buffer for all SDS-PAGE 
gels. For each pocket 5-25 μg of protein lysate were mixed with 5 x SDS-PAGE 
loading buffer and heated for 5 min to 95°C before being loaded. In case of 
precipitated protein, the maximum volume possible per well was loaded (see 2.32). 
5 μL of Page Ruler Plus Prestained Protein Ladder (Fermentas) were used as a 
marker. The gel was run at a voltage of 50 V for 30 min, followed by 110 V until the 
bromophenolblue tracking dye had left the gel. 
Table 8 recipes for PAGE gels 
  7.5% 10% 12% 15%  stacking gel
water mL 2.379 1.960 1.625 1.122 Water 1.5 
1.6 M Tris pH 8.8 mL 1.250 1.250 1.250 1.250 0.5 M Tris pH 6.8 0.625 
10% SDS μL 100 100 100 100 10% SDS 25 
30% Acrylamid/Bis; 29:1 
(Bio-Rad) 
mL 1.256 1.675 2.010 2.513 
 
30% Acrylamid/Bis; 
29:1 
325 
10% APS (Merck) μL 25 25 25 25 APS 25 
TEMED (Amresco) μL 5 5 5 5 TEMED 2.5 
  
For Western blotting, separated proteins were transferred to a PVDF membrane 
using the tank transfer system (Gallagher, Winston et al., 2008). Before assembly of 
the blotting sandwich, the PVDF membrane was activated with methanol, rinsed 
thoroughly with tap water and equilibrated in Towbin Buffer (25 mM Tris; 
192 mM Glycin; 5% MeOH) which was also used as transfer buffer. Transfer was 
performed at a current of 200 mA for 2 h at 4°C with a –20°C cooling pack in the 
tank. 
Following transfer, the membrane was rinsed with distilled water and protein bands 
were visualized using Ponceau S staining. The membrane was incubated with 
Ponceau S Solution (0.5 g/L Ponceau S (Sigma); 1 mL/L glacial acetic acid 
(Gallagher, Winston et al., 2008)) for 5 min. Background staining was removed by 
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washing several times with distilled water. Staining was documented using a 
photocopier. 
Following incubation, membranes were blocked with TBST-M (TBS: 8 g/L NaCl; 
0.2 g/L KCl; 3 g/L Tris; pH 7.4; T: 0.1% Tween 20 (Sigma); M: 5% skim milk powder 
(Fluka)) for 1 h on a shaker at RT. Membranes were then washed 3 x 5 min with 
TBST and incubated in primary antibody solution overnight in a 15 mL Falcon tube 
on a shaker at 4°C. See Table 9 for antibodies used. The next day, membranes were 
washed 3 x with TBST and incubated in secondary antibody solution for 1 h on a 
shaker at RT. This was followed by washing 3 x with TBST and 2 x with TBS before 
incubation upside-down on a parafilm with Immun-Star WesternC reagent (Bio-Rad) 
and visualization of the signal with Hyperfilm ECL (GE Healthcare). 
Table 9 antibodies used for western blotting 
antibody dilution supplier diluent size of target
mouse-anti-Activin A 1:500 AbD Serotec; MCA950S TBST-M 47/13kDa* 
mouse-anti-GFP 1:2000 Roche; 11814460001 TBST-M 27kDa 
mouse-anti-INHBE 
1:500 
Nigel Groome;  
(Vejda, Cranfield et al., 
2002) TBST-M 39/12kDa* 
rabbit-anti-Akt 1:1000 Cell Signaling; 9272 TBST-5%BSA 60kDa 
rabbit-anti-INHBE 
1:500 
Wolfgang Schneider; 
(Grusch, Drucker et al., 
2006) TBST-M 39/12kDa* 
rabbit-anti-p44/42-MAPK 1:1000 Cell Signaling; 9102 TBST-5%BSA 44/42kDa 
rabbit-anti-Phospho-Akt 1:1000 Cell Signaling; 9271 TBST-5%BSA 60kDa 
rabbit-anti-Phospho-p44/42-MAPK 1:1000 Cell Signaling; 9101 TBST-5%BSA 44/42kDa 
rabbit-anti-Phospho-S6 1:1000 Cell Signaling; 2211 TBST-5%BSA 32kDa 
rabbit-anti-Phospho-Smad 1/5 1:1000 Cell Signaling; 9516 TBST-5%BSA 60kDa 
rabbit-anti-Phospho-Smad 2 1:1000 Cell Signaling; 3101 TBST-M 60kDa 
rabbit-anti-S6 1:1000 Cell Signaling; 2217 TBST-5%BSA 32kDa 
rabbit-anti-Smad 2/3 1:1000 Cell Signaling; 3102 TBST-5%BSA 60kDa 
rabbit-anti-Smad 5 1:1000 Cell Signaling; 9517 TBST-5%BSA 60kDa 
rat-anti-HA 1:1000 Roche; 11867423001 TBST-M n/a 
goat-anti-rabbit-HRP 1:10000 Dako; P0448 TBST-M n/a 
goat-anti-rat-HRP 1:10000 Pierce; 31470 TBST-M n/a 
rabbit-anti-mouse-HRP 1:10000 Dako; P0260 TBST-M n/a 
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rabbit-anti-rat-HRP 1:1000 Dako; P0450 TBST-M n/a 
*pro-protein/mature protein, monomeric 
 
2.36. SMAD phosphorylation assay 
 
For determination of smad phosphorylation, HepG2 cells (smad 2) and HCT116 or 
HT1080 cells (smads 1 and 5) were seeded into 6-wells at about 500 000 cells per 
well in full medium. The next day, medium was removed and cells were washed 2 x 
with PBS. 0.5 mL of serum free medium conditioned media or purified recombinant 
cytokines were added, and the cells were incubated for 30 min in the incubator. For 
competition assays, wells were pre-incubated with 0.5 mL conditioned medium for 
30 min in the incubator before the addition of activin A or BMP-2. Cells were then 
harvested as described under 2.33 and cell lysates were subjected to gel 
electrophoresis and western blot. 
 
2.37. Microscopy 
 
Light, fluorescence and fluorescence time-lapse microscopy were performed using an 
Eclipse TE300 microscope (Nikon), a Digital Sight DS-5M (Nikon) or SPOT INSIGHT 
(Diagnostic Instruments) CCD camera and MetaMorph software (Molecular Devices). 
All microscopy was performed at room temperature. 
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3. Results 
 
3.1. Construction of expression vectors coding for tagged 
and untagged versions of activins A and E 
 
In order to investigate the effects of activin E as well as activin heterodimers 
containing the beta E subunit, an expression system was set up, as neither activin E 
nor any of the possible heterodimers are available commercially. 
Since (i) purification of activins through classical biochemical means has been 
described as rather difficult (Smith, Price et al., 1990; Smith, Yaqoob et al., 1988) 
and because of (ii) reliable antibodies to activin beta E are not available, it was 
decided to create several tagged versions of the protein. Before my involvement in 
the project, the cDNA for human activin beta E had already been cloned into the 
multiple cloning site of a pIRESneo3 vector (Clontech) for the expression in 
mammalian cells (pIRES Hs AßE / D32), by other members of the lab of Michael 
Grusch. In a similar manner, an expression vector for human activin beta A had been 
created (pHs INHBA IRESpuro / D41). In addition, a version of activin beta E 
containing the hemagglutinin (HA) sequence as a tag on the N-terminus of the 
mature form, right after the cleavage site of the prodomain had been produced 
(pHsAßE-HA-IRESpuro / D46).  
This particular location for the tag had been chosen because of reports that a 
C-terminal tag rendered activin A inactive (Pangas & Woodruff, 2002), while a tag at 
the N-terminus of the prodomain would be cleaved off with the pro-peptide. A similar 
approach had been suggested and tested for activin A and chimeras of this protein 
by other groups (Fischer, Park et al., 2003). To confirm that this modification does 
not (necessarily) change the (unknown) biological activity of the protein, we also 
attempted to create an expression vector coding for a version of activin beta A, 
bearing the identical tag at the corresponding location (see 3.1.2). 
Other approaches, like the expression in bacteria or the expression of the mature 
peptide only, had to be ruled out because the prodomain on the one hand renders 
the protein inactive if not cleaved off (Mason, Farnworth et al., 1996), but on the 
other hand is required for correct folding (Gray & Mason, 1990). 
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Since other reports suggested that variants of activin A containing a tag at the 
C-terminus would retain their biological activity (Munz, Smola et al., 1999) and that 
C-terminally tagged activin E would still be able to bind to follistatin (Hashimoto, 
Tsuchida et al., 2002), it was decided to also create several C-terminally tagged 
versions of activin beta E. In particular we created one version containing the V5-His 
tag (cloned into Invitrogen's pcDNA3.1/V5-His vector by members of the lab of 
Michael Grusch) at the C-terminus, and a chimerical protein in which activin beta E is 
fused to the N-terminus of enhanced green fluorescent protein (EGFP). 
See Figure 8 for an overview of the different activin constructs created, and a list of 
the vectors on which they are encoded. 
 
 
activin variant expression cassette found on vector type of vector 
activin beta A pHs INHBA IRESpuro / D41 
INHBA_HA_IGP / G9 
mam expr 
baculovirus (mam expr) 
activin beta A – HA *pINHBA_HA / D60 
*INHBA_HA_IGP / G16 
mam expr 
baculovirus (mam expr) 
activin beta E pIRES Hs AßE / D32 
INHBE_IGP / G14 
mam expr 
baculovirus (mam expr) 
activin beta E – HA pHsAßE-HA-IRESpuro / D46 
INHBE_HA_IGP / G12 
INHBE_HA_PPH / G19 
mam expr 
baculovirus (mam expr) 
baculovirus (insect expr) 
activin beta E – V5His pcDNA-3-1-HsAßE-V5-HisB mam expr 
activin beta E – GFP pINHBE_GFP / D57 mam expr 
* later turned out to contain a frameshift resulting in a premature stop codon 
 
Figure 8 different variants of activin subunits and the vectors they are encoded on; 
mam expr, mammalian cell expression vector 
insect expr, insect cell expression vector 
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3.1.1. Construction of a mammalian expression vector coding for 
human activin beta E fused to EGFP (pINHBE_GFP / D57) 
 
pINHBE_GFP was created by amplifying the cDNA sequence for activin beta E from 
pIRES Hs AßE / D32 with primers removing the stop codon and containing a 
cleavage site for the restriction enzyme Bsp120I in the forward and reverse primer 
(HsßE for around ATG; ßE removing stop codon; see Table 10). PCR was performed 
using Pfu polymerase with an initial cycle of 3 min denaturation at 95°C, 50 sec 
annealing at 50°C and 4 min elongation at 72°C. This was followed by 37 cycles of 
50 sec denaturation at 95°C, 50 sec annealing at 50°C and 2 min elongation at 72°C. 
The last cycle was performed with 50 sec denaturation at 95°C, 50 sec annealing at 
50°C and 4 min elongation at 72°C. The PCR product was cleaned-up using the 
Wizard SV Gel and PCR Clean-Up System and digested with 10 units of Bsp120I 
(Fermentas) at 37°C for 3 h. The reaction product was run on a 2% gel and the 
band corresponding to the expected product of 1064 bp was excised and again 
cleaned-up using the Wizard SV Gel and PCR Clean-Up System. As a target vector, 
pEGFP-N3 (Clontech) was digested with Bsp120I, dephosphorylated with CIAP and 
purified by being run on a gel and extracted with the 
Wizard SV Gel and PCR Clean-Up System. 
Both fragments were then ligated using T4 DNA ligase and rapid ligation buffer and 
transformed into JM109 cells. Overnight cultures were created from several colonies, 
and those containing the correct plasmid were identified by digesting the purified 
plasmid (boiling lysis) with StuI and Eco147I (both Fermentas) see Figure 9. 
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Figure 9 analytical digest of pINHBE_GFP; 
Expected fragments: 3885 bp and 1938 bp 
 
3.1.2. Construction of a mammalian expression vector coding for 
human activin beta A containing a HA-tag at the N-terminus of 
the mature form (pINHBA_HA / D60) 
 
 
Figure 10 PCR strategy for the creation of pINHBA_HA; 
PCR was used to add the HA-tag N-terminally of the proform and at the C-terminus of the mature 
peptide in two separate reactions (PCR 1, reaction A and B); the presence of the same sequence in 
both products allowed for an annealing of these two sequences in a second reaction – primers for the 
termini of the full length sequence were used to amplify the sequence for activin beta A – HA (PCR 2) 
 
To insert a HA-tag C-terminally of the cleavage site in activin beta A, a PCR approach 
using four primers and two sequential amplifications was used (see Figure 10 for an 
outline of the strategy). In a first PCR (reaction A) one primer binding to the DNA 
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sequence coding for the N-terminus of activin beta A (Hs Activin beta A for1) and 
one binding to the sequence for C-terminus of the proform, but also containing the 
sequence for the HA-tag in addition (pro-AßA-HA rev) were used for the 
amplification. As a template, a plasmid containing the full length cDNA sequence of 
INHBA (pHs INHBA IRESpuro / D41) was used. Initial denaturing was 3 min at 95°C, 
followed by 40 cycles with 30 sec denaturing at 95°C, 30 sec annealing at 61.5°C 
and 2 min elongation at 72°C, and a final elongation for 4 min at 72°C. In a separate 
reaction (reaction B) with the same conditions, a primer containing the HA-tag 
sequence and binding to the N-terminus of the mature form (HA-Tag-AßA-mat), and 
one primer binding to the C-terminus of INHBA (Hs Activin beta A rev1) were used 
with the same template as before. The two products were subjected to gel 
electrophoresis. The DNA fragments running at the expected heights (see Figure 11, 
left) were excised and purified with the Wizard SV Gel and PCR Clean-Up System. For 
a second PCR reaction, the products from the first set of reactions were mixed 
(1/100 of each of the total purified products) and amplified using the two primers 
binding to the N- and C-termini of full length INHBA (Hs Activin beta A for1 and 
Hs Activin beta A rev1). Initial denaturing was 3 min at 95°C, followed by 40 cycles 
with 30 sec denaturing at 95°C, 30 sec annealing at 57°C and 3 min elongation at 
72°C, and final elongation for 4 min at 72°C. The product was again subjected to gel 
electrophoresis (see Figure 11, right), purified, phosphorylated with PNK and ligated 
into the vector pIRESneo3 which had been digested with EcoRV (Fermentas) and 
dephosphorylated. Following transfection into JM109 cells, overnight culture and 
boiling lysis miniprep, the identity of the plasmid was confirmed by digest with 
BamHI (Fermentas) yielding the expected fragments of 1312 bp and 5274 bp (not 
shown). 
  
Figure 11 products of the first set of PCR reactions for the creation of pINHBA_HA; 
sizes of product are as expected 
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Unfortunately, sequencing of the vector later showed that a error had occurred 
during the creation of the fragment. It resulted in a frameshift and premature stop 
codon about 200 bases from the 3’ end of the expected open reading frame. Despite 
thorough re-evaluation of the strategy, the exact reason for this remained unknown. 
As a repetition of the PCR yielded the correct product, an error of the polymerase 
during the initial amplification procedure is the most likely explanation. 
Table 10 PCR primers used 
primer Name sequence 5’ to 3’ internal designation 
HsßE for around ATG TATTAGGGCCCAGGAGCATGCGGCTCCCTGA 83
baculo_QPCR_for CCCGTAACGGACCTCGTACTT 201
baculo_QPCR_rev TTATCGAGATTTATTTGCATACAACAAG 202
CMV_QPCR_for CCCATAGTAACGCCAATAGG 203
CMV_QPCR_rev CGTAGATGTACTGCCAAGTAGG 204
gent_rev ATCAGCCGGACTCCGATTACC 205
GFP-rev CTGAACTTGTGGCCGTTTAC 41
HA-Tag-AßA-mat TACCCATACGATGTTCCAGATTACGCTTTGGAGTGTGATGGCAAGG 190
Hs Activin beta A for1_EcoRI CGTGAATTCGGATGCCCTTGCTTTGG 197
Hs Activin beta E rev1 CCCAGTTCCTGGAAGTCTAC 6B
Hs Activin beta A for1 CAGGATGCCCTTGCTTTGG 1A
Hs Activin beta A rev1 TGGGCTGGGCAACTCTATG 1B
IRES rev2 TTATCATCGTGTTTTTCAAAGG 18B
M13 for (-40) Invitrogen GTTTTCCCAGTCACGAC 21A
pro-AßA-HA rev AGCGTAATCTGGAACATCGTATGGGTAGCCCCGCCGACGCCGGCGAT 189
ßE removing stop codon TATTAGGGCCCATGCTGCAGCCACAGGCCTCCA 85
 
3.1.3. Prediction of furin cleavage sites in different activin 
variants 
 
To get a hint whether or not the addition of epitope tags (in particular close to the 
cleavage site of the protein) would have an effect on the processing of the activin 
subunits, the sequence of the expected full length protein was evaluated using a 
publicly available neuronal network for the prediction of furin cleavage sites (Duckert, 
Brunak et al., 2004). For results see Figure 12. 
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A B 
activin beta A activin beta A - HA 
C D 
activin beta E activin beta E - HA 
 E 
 
 activin beta E - GFP 
Figure 12 graphical representation of prediction of the site of cleavage by furin; 
protein sequences of wildtype activin subunits beta A and beta E (A, C) as well as tagged activin 
subunits beta A – HA (B), beta E – HA (D) and beta E – GFP (E) were analyzed for the presence of 
furin cleavage sites (x-axis: position in the amino acid sequence of the polypeptide, y-axis: relative 
likelihood of cleavage by furin); predicted cleavage sites for wildtype activins are in accordance with 
published data, the presence of tags does not have a major effect on cleavage in the prediction 
 
An evaluation of the suggested cleavage sites in the wildtype forms of activin beta A 
and activin beta E (D41 and D32 respectively) shows that they coincide with the 
cleavage sites reported (Hashimoto, Tsuchida et al., 2002; Mason, Farnworth et al., 
1996) and our own observations for activin A (see below). 
The HA-tag is predicted to slightly reduce the effectiveness of the cleavage site, 
while the C-terminal fusion to GFP should not affect processing. 
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3.2. Stable cells lines 
 
In order to have continuous access to recombinantly produced activins without the 
need to transfect cells and verify the expression of the protein for every experiment, 
CHO-DHFR- and HEK293 cells were transfected with vectors coding for various 
variants of different activins and selected for stable integration of the plasmid into 
their genome. As described in the materials and methods section, CHO-DHFR- cells 
were cotransfected with a plasmid expressing DHFR to increase their expression of 
the gene of interest by treatment with methotrexate once stable clones had been 
selected. See Table 11 for a list of stable cell lines that were created during the 
course of the diploma thesis. 
CHO cells were preferentially used for the creation of stable clones, as they proved to 
be fast growing and very resistant to unfavorable conditions like the incubation with 
serum-free medium. They have often been described as ideal for the expression of 
proteins (Kingston, Kaufman et al., 2002), and have been used successfully for the 
production of activin A in the past (Arai, Tsuchida et al., 2006). 
 
Table 11 cell lines created 
cell line plasmid used for transfection MTX transgene to be expressed / function
*293-D43 pcDNA-3-1-HsAßE-V5-HisB  activin beta E - V5His
293-D48 pACVR2B-ECFP  cctivin receptor 2B - ECFP
293-D49 BMPR1B-EYFP  BMP receptor 1B - EYFP
CHO-A69 pECFP-IRESpuro  ECFP / control
CHO-A71 pIRES-puro  puromycin resistance marker / control
CHO-A8 pcDNA3  neomycin resistance marker / control
CHO-D32 pIRES Hs AßE 80 nM activin beta E
*CHO-D43 pcDNA-3-1-HsAßE-V5-HisB  activin beta E - V5His
CHO-D46 pHsAßE-HA-IRESpuro 320 nM activin beta E - HA
CHO-D57 pINHBE_GFP 5 uM activin beta E - GFP
**CHO-D60 pINHBA_HA  activin beta A - HA
* the use of the cell line was stopped as western blotting gave no evidence for the expression of the 
transgene; CHO-D43 cells in addition showed significantly faster growth than cell lines expressing 
other versions of INHBE and had a morphology that resembled CHO cells transfected with the 
resistance gene only 
** D60 turned out to contain an error in the sequence (see 3.1.2) 
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Unfortunately, several attempts to create a cell line stably expressing the wildtype 
form of activin A failed. – Stable clones appeared and grew to about 25% 
confluence, but 75-90% always died upon reseeding, making expansion impossible. 
 
Apart from the determination of protein expression by immunological techniques (see 
below), established cell lines were investigated for their growth characteristics 
(3.5.1) and their morphology. It soon became evident, that expression of both 
wildtype and HA-tagged variants of activin beta E resulted in a much more spread 
out morphology of CHO cells in comparison to cells just expressing the resistance 
markers to the respective antibiotics used for selection (see Figure 13). 
 
 
CHO-A71 CHO-D32 CHO-D46 
Figure 13 phase contrast images of CHO cells stably expressing variants of activin beta E 
or resistance genes only; all images were taken at the same magnification; 
cells of cell lines CHO-D32, expressing activin beta E, and in particular CHO-D46, expressing 
activin beta E – HA, have significantly distinct morphologies than CHO-A71 cells, expressing the 
puromycin resistance marker only 
 
3.3. Creation of a baculovirus expression system for activins 
 
In order to be able to produce large amounts of recombinant activin variants in 
different cell lines, we established a baculoviral expression system for different 
activins. 
Based on the Bac-To-Bac Baculovirus Expression System (Invitrogen), the group of 
Michael Grusch had previously adapted the system for efficient expression of genes 
in mammalian cells (Lackner, Genta et al., 2008). In brief, the system makes use of 
transfer vectors (in the original system called Fastbacs), containing a CMV promoter, 
a multiple cloning site (MCS) to insert the gene of interest (GOI), and a fusion 
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protein between EGFP and a puromycin resistance protein, encoded on the same 
bicistronic mRNA, separated by an IRES sequence. Baculoviral systems like this, 
containing a mammalian expression cassette, are generally referred to as BacMams 
(Fornwald, Lu et al., 2007). 
The expression cassette was transferred into the virus genome (bacmid) via 
recombination, taking place in the E. coli strain DH10 containing the bacmid and a 
recombinase. See Figure 14 for a general outline. Upon successful recombination via 
Tn7 sites, the gene coding for the lacZalpha protein fragment was destroyed, 
resulting in a loss of blue staining of the respective colonies when plated on 
X-Gal / IPTG containing agar plates. White colonies were checked for the presence of 
the integration cassette using PCR and used for the inoculation of overnight cultures. 
Bacmid DNA was isolated from these cultures and used to transfect Sf9 insect cells 
which then produce the virus. When cell supernatant containing a sufficiently high 
virus titer (see below) had been created by re-infecting Sf9 cells with cell 
supernatant from previously infected cells, the supernatants were directly used to 
infect mammalian cells. Successful infection was determined by green fluorescence 
resulting from the expression of the GFP-containing fusion protein from the same 
mRNA as the gene of interest (see Figure 22). 
 
Figure 14 transfer vector and bacmid 
the transfer vector containing the expression cassette is created by standard cloning procedures; 
integration into the virus genome (bacmid) takes place via Tn7 sites in DH10 E. coli cells; successful 
recombination is assessed by PCR using primers binding on the original bacmid and the region 
donated by the transfer vector, respectively 
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3.3.1. Optimization of procedures for production and 
quantification of baculoviruses 
 
During the construction of new baculoviruses (see below), we were able to optimize 
the production of baculoviruses and determination of the virus titer, both in respect 
of financial resources and hands on time required. 
In particular, we established the use of plasmids obtained by boiling lysis miniprep 
for the transformation of DH10 cells and the use of the primer pair 
M13 for (-40) Invitrogen and gent_rev as opposed to M13 for (-40) Invitrogen and 
IRES rev2 (see Table 10) directly on white colonies (colony PCR) instead of on 
purified plasmids (initial denaturing 3 min, 95°C; 33 cycles with 30 sec denaturing, 
95°C, 30 sec annealing 60°C, 1 min elongation, 72°C, final elongation 2 min, 72°C). 
This on the one hand made it possible to immediately proceed to the next step with 
the miniprep used for checking of the transfer vector, by this saving one day in the 
production of a virus. On the other hand, the PCR modification gave rise to a much 
smaller product (800 bp instead of 4 200 bp), significantly reducing the time for the 
PCR and making it unnecessary to isolate bacmid DNA from several possible 
candidates. 
Much more significant however was the establishment of QPCR for the determination 
of baculovirus titer. While the previously used BacPAK Baculovirus Rapid Titer Kit 
(Clontech) (Kitts & Green, 1999) produced good results, it was both time consuming 
and expensive. Therefore, we switched to the use of QPCR as suggested by Lo et al. 
(Lo & Chao, 2004). In addition to the primers baculo_QPCR_for and 
baculo_QPCR_rev, described in their study, we designed the primers CMV_QPCR_for 
and CMV_QPCR_rev, binding inside the CMV promotor, to be able to quantify viruses 
containing the CMV expression cassette only. For both primer pairs, we determined a 
formula to calculate the virus titer in Pfu/mL from the Ct-values obtained by QPCR of 
different dilutions of a baculovirus with known titer (previously determined by 
BacPAK Baculovirus Rapid Titer Kit). For standard curves see Figure 15, for formulas 
see 2.29. Typical virus titers were in the range of 3 x 106 - 3 x 108 Pfu/mL. In 
general, results from the determination of the virus titer of one sample with the two 
different primer pairs were in good agreement. 
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Figure 15 standard curves for determination of the baculotiter from Ct-values obtained by 
QPCR; 
curves were created by determining the Ct-values of different dilutions of a baculovirus with known 
titer 
 
3.3.2. Construction of a baculovirus for the expression of 
HA-tagged activin beta A (INHBA_HA_IGP / G16) 
 
The sequence coding for HA-tagged activin A was cloned into the transfer vector 
pFastbac IRES EGFPpuro / A82 by PCR amplification from the D60 vector (see 3.1.2) 
with the primers Hs Activin beta A for1_EcoRI and Hs Activin beta A rev1 (initial 
denaturing 3 min 95°C, 40 cycles of 30 sec 95°C, 50 sec 55°C and 3 min 72°C; final 
elongation 4 min 72°C). After phosphorylation of the sequence of interest, it was 
inserted into the vector A82 which had been cut with Eco47III (Fermentas) and 
dephosphorylated with CIAP. Plasmids from the resulting colonies were checked for 
their identity by digest with PstI (Fermentas) and used to transform DH10 cells. 
Integration into the bacmids of white colonies was checked with colony PCR with the 
primers M13 for (-40) Invitrogen and IRES rev2 (initial denaturing 5 min 95°C, 
33 cycles of 50 sec 95°C, 50 sec 60°C and 8 min 72°C; final elongation 2 min 72°C). 
Sf9 cells were transfected with the purified bacmid and isolated virus again checked 
for its identity with primers Hs Activin beta A for1 and GFP-rev (initial denaturing 
2 min 95°C, 33 cycles of 30 sec 95°C, 30 sec 55°C and 3.5 min 72°C; final 
elongation 5 min 72°C). 
Like the template vector D60 that had given rise to the fragment inserted into the 
transfer vector, the resulting baculovirus must unfortunately also contain a mutation 
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in the sequence coding for activin beta A – HA, resulting in a frameshift in the 
mature part (see 3.1.2). 
 
3.3.3. Construction of a baculovirus for the expression of wildtype 
activin beta E (INHBE_IGP / G14) 
 
While a baculovirus containing an expression cassette for HA-tagged activin beta E 
and wildtype activin beta A had already been created by other members of the group 
of Michael Grusch, we decided to create an expression vector for 
wildtype activin beta E. To do so, we digested the vector D32, containing the cDNA 
for full length human activin beta E with NdeI and HpaI and cloned it into the 
transfer vector A82 which had been cut with NdeI and Eco47III and 
dephosphorylated with CIAP (all: Fermentas). After confirmation of the identity of the 
vector by digest with Eco47III, it was transformed into DH10 cells. Integration of the 
insert was confirmed as outlined for G16 (see 3.3.2). Identity of the virus produced 
by infected Sf9 cells was checked by PCR with primers M13 for (-40) Invitrogen and 
Hs Activin beta E rev1 (same conditions as for final check of G16 – see 3.3.2). 
 
3.3.4. Construction of a baculovirus for the expression of 
HA-tagged activin beta E in insect cells (INHBE_HA_PPH / G19) 
 
As insect cells had previously been used successfully for the production of activins 
(Wuytens, Verschueren et al., 1999), we decided to test the same approach for the 
production of HA-tagged activin beta E. The transfer vector was created by cloning 
the INHBE-HA containing fragment of the vector D46 (3.1) into the MCS of 
pFastbac-1 / A93, by digesting both with HindIII (Fermentas). Identity was 
confirmed by digest with SnaBI (New England Biolabs). Colonies of DH10 cells in 
which the expected bacmid had been created by recombination were identified by 
PCR with primers M13 for (-40) Invitrogen and gent_rev as outlined under 3.3.1. 
Finally, production of a virus by Sf9 cells containing the correct expression cassette 
was checked by PCR with primers M13 for (-40) Invitrogen and Hs Activin beta E 
rev1 (same conditions as for final check of G14 – see 3.3.3). 
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3.4. Determination of expression of wild type and tagged 
versions of Activin A and E 
3.4.1. Different precipitation techniques 
 
To determine the ideal method to precipitate activins from serum free cell 
supernatant, different approaches as proposed by Zellner et al. (Zellner, Winkler et 
al., 2005) and  Jiang et al. (Jiang, He et al., 2004) were tested. In addition to protein 
precipitation with EtOH (addition of 4 volumes (V) of 100% EtOH; incubation at –
20°C o/n) which was used as the standard method, acetone (addition of 4 V of 
acetone; –20°C o/n), trichloroacetic acid (TCA, Merck; 1/3 V of 6.1 N TCA; 1 h 4°C), 
ammonium sulfate (AMS, Merck; addition of 9 V saturated AMS solution; mixing on 
ice for 30 min) and chloroform-methanol (addition of 4 V MeOH; 1 V chloroform 
(Merck); 3 V H2O; 1 min 15 000 g; removal of upper phase; 4 V (original volume) 
MeOH; 2 min 15 000 g; removal of supernatant) were used to precipitate protein 
from conditioned media. In all cases except for chloroform-methanol, precipitation 
was completed by centrifugation at 15 000 g at 4°C for 15 min and removal of the 
supernatant. All pellets were resuspended in 1 x SDS-PAGE loading buffer, 
neutralized where necessary and heated to 95°C before being loaded onto the gel. 
 
 
Figure 16 comparison of different methods for the precipitation of HA-tagged 
activin beta E from cell supernatant; 
conditioned medium (5 mL per lane) from a confluent T25 flask of CHO cells expressing 
activin beta E – HA was precipitated as described in the text; the membranes were probed with 
antibody against the HA-tag 
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In Figure 16 it can clearly be seen that precipitation with ethanol yielded the best 
results. While there is still a band at the correct height visible in case of precipitation 
with acetone, all other precipitation methods failed to produce the expected results. 
Although optimizing the different procedures might lead to more similar results, we 
decided to use EtOH as the standard means of isolating protein from cell supernatant 
as it is also straight forward, reliable and cost-effective. 
 
3.4.2. Western blot 
 
Western blots were the main way of determining the expression of the gene of 
interest. In a first line of experiments, it was tested whether or not it was possible to 
isolate and visualize different activins overexpressed in mammalian cells. To do so, 
HEK293 cells were transfected with different plasmids coding for members of the 
activin family. Among them was pHs INHBA IRESpuro / D41. Protein from 
conditioned media from cells transfected with the construct was precipitated and run 
on a SDS-PAGE gel, next to purified recombinant activin A (R&D) and, following 
western blotting, analyzed by immunodetection with mouse-anti-Activin A antibody 
(see Figure 17). 
 
 
Figure 17 recombinant and exogenously expressed activin A under reducing and 
non-reducing conditions; 
purified recombinant activin A (rh Act A) and precipitate of conditioned media of HEK293 cells (one 
T25 flask), transiently expressing activin beta A (cm293 AßA) were run on a gel under reducing and 
non-reducing conditions; the membrane was probed with antibodies against activin A; the mature 
dimeric form of activin beta A (activin A) is marked by black arrows 
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In accordance with the results described by Smith et al. (Smith, Price et al., 1990), 
we detected a band for the mature dimeric activin A (marked by an arrow) under 
non-reducing conditions at a position a little below 26 kDa, and a band for mature 
monomeric activin beta A under reducing conditions below 17 kDa. While the band 
corresponding to the monomeric version can be found in the supernatants of HEK293 
cells run both under reducing and non-reducing conditions, the band corresponding 
to the mature dimer (arrows) is only present under non-reducing conditions. This 
indicates that activin A can be expressed in, and is processed correctly by HEK293 
cells. 
The same approach was used to determine the expression of human activin A in 
HepG2 cells that had been infected with the G9 baculovirus, containing an expression 
cassette for INHBA. 
 
 
Figure 18 supernatants from HepG2 cells infected with baculovirus for activin beta A 
expression (G9); 
protein was precipitated from conditioned media from HepG2 cells growing in 6-wells, either untreated 
(cmG2) or transduced with a baculovirus containing an expression cassette for activin beta A 
(cmG2 AßA); recombinant activin A (10 ng) was used as a control 
 
It can be seen from Figure 18, that infection of HepG2 cells with G9 baculovirus, 
containing an expression cassette for activin beta A results in high level expression of 
the protein of interest. The bands appear specific, as they are almost non-existent in 
the cell supernatant of uninfected HepG2 cells. The minor band in the HepG2 lane 
most likely results from spill over during the loading of the gel as HepG2 cells 
normally do not express the INHBA gene (Chen, Woodruff et al., 2000). The band 
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found in supernatant of HepG2 cells transduced with the G9 virus between 43 kDa 
and 55 kDa most likely corresponds to the monomeric proform of activin A (47 kDa 
without glycosylation) which was also found by other researchers (Arai, Tsuchida et 
al., 2006). 
 
Due to the low affinity (50 ng but not 10 ng of recombinant mature peptide of 
activin beta E (Biopharm) could be detected with mouse-anti-INHBE antibody; see 
Figure 19; left) and high cross-reactivity of all antibodies raised against activin beta E 
(data not shown) that we had access to, we were not able to visualize the wildtype 
form of the protein artificially expressed from pIRES Hs AßE / D32 in different cell 
systems. Because of this, it was never possible to prove the expression of wildtype 
activin E, and we had to use RNA expression (not shown) and other criteria like the 
morphology and growth characteristics of stable cell lines (see 3.2 and 3.5.1) in 
comparison to those expressing tagged versions of the protein to judge the 
expression of the protein. 
For that reason, the cell line CHO-D46, stably expressing the HA-tagged version of 
activin beta E, was established and used for many of the experiments trying to 
determine the biological function of activin beta E.  
In addition, the fusion protein between activin beta E and GFP, expressed by the 
CHO-D57 cell line (see also Figure 22), was used for detection of the secreted 
protein and several of the experiments. 
 
Figure 19 shows western blots of recombinant mature human (rh) activin beta E, 
expressed in E. coli, detected with mouse-anti-INHBE antibody, and protein from 
supernatant from CHO-D46 cells as well as cells infected with the G12 baculovirus 
containing the same expression cassette (both detected with an antibody against the 
HA epitope). 
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Figure 19 western blot of recombinant activin beta E and HA-tagged activin beta E 
produced by the CHO-D46 cell line and HepG2 cells infected with the baculovirus for 
activin beta E-HA expression (left);  
eluate from anti-HA-agarose pulldown of activin beta E under reducing and non-reducing 
conditions (middle); 
pulldown of activin beta E – HA containing supernatants (right); 
conditioned media of CHO cells expressing activin beta E – HA (cmC AßE-HA) or of HepG2 cells either 
untreated (cmG2) or transduced with the G12 baculovirus containing an expression cassette for 
activin beta E – HA (cmG2 AßE-HA) were subjected to gel electrophoresis and western blot under 
reducing conditions – pro-protein and the mature form of activin beta E could be detected (left); 
under non-reducing conditions, large aggregates were detected (middle);  
pulldown of similar CHO supernatants using anti-HA-agarose (pd cmC AßE-HA), followed by western 
blot under reducing conditions yielded bands for the pro-protein and the mature protein (marked by 
arrows), as well as a signal most likely caused by eluted antibody (asterisk) (right); see text for 
additional information 
 
 
Antibodies directed against the wildtype protein detect a clear band below 17 kDa 
when (large amounts of) recombinant activin beta E are loaded onto the gel. A band 
similar in height can also be seen in the supernatant of CHO-D46 cells and HepG2 
cells expressing the same construct after viral transduction, but not in case of 
untransfected HepG2 cells. It is also in accordance with a band for monomeric 
mature activin beta E (expected: 13.5 kDa) described in a mouse overexpressing this 
protein (Hashimoto, Ushiro et al., 2006). A much more intense band however, which 
is also described in the same publication, is detected between 43 kDa and 34 kDa. In 
all likelihood it is caused by the proform (expected to be 39.6 kDa without 
glycosylation). Closer evaluation shows that it is indeed a double band (compare to 
Figure 16), probably caused by versions of the protein with a different glycosylation 
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status (Vejda, Cranfield et al., 2002). It has to be noted, that while a band around 
43 kDa could be detected in almost every precipitate from the supernatant of 
CHO-D46 cells, bands around 17 kDa were rarely detected (see for example Figure 
16), despite precipitating similar amounts of media. Given that the signal of the 
~43 kDa band in Figure 19 is so much more intense than the signal of the smaller 
bands, it is not surprising that no smaller bands can be seen in Figure 16 or similar 
blots, as the signal of the high molecular weight bands is already much weaker in 
that case. The exact reasons for this however remain unknown. 
It was discovered later, that the (largely) insoluble fraction resulting from 
precipitation with EtOH contained significant amounts of activin. Loading both the 
(urea) soluble and insoluble fractions together on gel (after the addition of 
SDS-PAGE loading buffer) repeatedly resulted in a much more intense signal, similar 
to that shown in Figure 19. 
Even more difficult is the interpretation of the results from gel electrophoresis under 
non-reducing conditions (see Figure 19 right). It seems that while some protein still 
exists in the unprocessed but monomeric form (around 43 kDa), a large part forms 
aggregates of several hundred kDa (compare to activin beta E - GFP below). 
 
Western blotting with anti-GFP antibody of precipitate from activin beta E - GFP 
expressing cells (CHO-D57) in general gave similar results (see 
 
Figure 20, left) as blotting of the HA-tagged variant. A band for the proform 
(66.2 kDa) was easily detected below 72 kDa under reducing and non-reducing 
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conditions. While a significant part of the protein seems to form a large complex 
under non-reducing conditions, preparing the sample in the presence of reducing 
agents results in a signal a little below 43 kDa which is likely to be caused by the 
mature monomeric fusion protein (40.1 kDa). The large band below 34 kDa is most 
likely caused by a contamination of the cell pool with GFP expressing cells. Evidence 
for this kind of contamination (fluorescent signal in the whole body of the cell as 
opposed to the secretory pathway only in some cells) was also observed by 
fluorescence microscopy (not shown). 
 
 
Figure 20 supernatants from CHO cells expressing activin beta E  - GFP 
media from CHO cells stably expressing activin beta E – GFP (cmC AßE-GFP; 5 mL, 1 T25 flask) as 
well as from CHO cells stably expressing CFP (cmC CFP) were precipitated and subjected to gel 
electrophoresis and western blotting under reducing and non-reducing conditions; membranes were 
probed with antibody against GFP; bands likely to be caused by activin variants are marked by arrows, 
while an asterisk designates a band probably caused by GFP only (see text) 
 
3.4.3.  Pulldown 
 
In order to purify activin beta E, and even be able to co-precipitate a possible 
receptor, preliminary pull-down experiments were undertaken using anti-HA-agarose 
beads. Early experiments gave promising results under reducing condition (see 
Figure 19, right). It was possible to precipitate proteins previously identified as 
proform and mature form of activin beta E – HA (marked by arrows, see above). The 
strong band identified by an asterisk is most likely caused by fragments of the 
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antibody eluted from the beads by boiling them in SDS-PAGE loading buffer 
containing 2-mercaptoethanol. The band was also found after incubation of the 
beads with control supernatants (not shown). Attempts at using less aggressive 
methods for eluting the bound protein (HA-peptide, acidic pH) showed that 
optimization of the methods used would be necessary. The same was true for eluting 
bound protein by boiling the beads in non-reducing SDS-PAGE buffer which resulted 
in a strong signal spreading over a large area in the range of >100 kDa, again 
indicating the formation of aggregates. 
 
3.4.4. Immunohistochemistry and fluorescence microscopy 
 
To test the expression of the gene of interest despite initial problems with the 
analysis of supernatants, we performed immunohistochemistry and fluorescence 
microscopy on stable cell lines and baculovirus transduced cells. 
While the use of antibodies directed against wildtype activin beta E failed in initial 
experiments (data not shown), it was possible to show that CHO cells stably 
transfected with the D46 plasmid and HepG2 cells transfected with the G12 
baculovirus indeed expressed the HA epitope. 
 
 
CHO-DHFR- CHO-D46 HepG2-G12 
Figure 21  immunohistochemical analysis of CHO cell lines and baculovirus transduced 
HepG2 cells 
untransfected CHO cells (left), CHO cells expressing activin beta E - HA (middle) and HepG2 cells 
transduced with baculovirus containing an expression cassette for the same protein (right) were all 
stained with anti-HA antibody; examples of positives cells are marked by white arrows; contrast 
increased 
 
In baculovirus transduced cells, transcription of the mRNA containing the gene of 
interest could also be assessed by fluorescence microscopy, as in most cases, a GFP 
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containing fusion protein was also encoded on the same mRNA as the gene of 
interest (see 3.3). In case of the fusion protein between activin beta E and GFP 
(encoded on D57, see 3.1.1), expression of the protein could be visualized directly. 
See Figure 22. 
 
 
MGC-G1 MGC-G12 CHO-D57 
Figure 22 fluorescence microscopy of virus transduced MGC cells and stable CHO cell lines 
MGC cells transduced with G1 virus containing an expression cassette for DsRed, used as control 
(left), HepG2 cells transduced with G12 virus for expression of activin beta E – HA 
(+ IRES EGFP-puro) (middle), and CHO cells stably expressing activin beta E – GFP under MTX 
selection (20nM; right) were examined by fluorescence microscopy; contrast increased 
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3.5. Effects of Activins A and E and their combination on 
different cell lines 
 
3.5.1.  Growth curves 
 
In a growth curve experiment, the effects of stable overexpression of different 
variants of activin E, in particular the HA-tagged version and the wildtype version, on 
the proliferation of CHO cells were determined. 
 
Figure 23 cell proliferation and cell diameter of CHO cell lines 
on day one, 50 000 cells per 6-well of the cell lines expressing activin beta E (CHO-D32), 
activin beta E - HA (CHO-D46) and two mock transfected cell lines (CHO-A8 and CHO-A71) were 
seeded each in six 6-wells in full medium. CHO-A71 and CHO-D46 were maintained under the 
selection antibiotic puromycin while CHO-A8 and CHO-D32 were grown in full medium only. Every 
day, cells from one 6-well each were detached by trypsinization and counted and measured 
 
Figure 23 clearly shows, that CHO cells overexpressing variants of activin E respond 
with reduced proliferation and increased cells size. The effect on cell proliferation is 
much more pronounced in the absence of a selection antibiotic, which has a strong 
anti-proliferative effect on its own (compare for example cell numbers for the two 
mock cell lines CHO-A8 and CHO-A71 cell lines). 
As it has previously been shown, that addition of activin A to the medium inhibits the 
proliferation of HepG2 cells (Razanajaona, Joguet et al., 2007), we determined if 
incubating HepG2 and Hep3B cells with conditioned media from the CHO cell lines 
expressing activin beta E and activin beta E – HA (CHO-D32 and CHO-D46 
respectively) and the two corresponding mock cell lines CHO-A8 and CHO-A71 (see 
Table 11) would influence the growth behavior of the incubated cells. 
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Figure 24 growth curves for HepG2 and Hep3B cells incubated with CHO cell line 
supernatants 
25 000 HepG2 or Hep3B cells were seeded per 12-well in full medium and left to attach for 24 h. 
Medium was then removed, cells were washed and supernatant of CHO cell lines (10% FBS), diluted 
1:3 with fresh growth medium with serum was added to the cells. The following days, every day one 
well each was harvested and the cells were counted; cmC conditioned medium from CHO cell lines, 
either expressing activin beta E (AßE) or transfected with a mock plasmid (mock); DMEM, fresh 
medium with 10% serum 
 
In both cases no clear difference between the effects of control and activin E 
containing supernatants could be seen. This in accordance with the data from the 
smad phosphorylation assay (see below) which (in contrast to the effects of 
activin A) does not show activation of the smad 2 signaling cascade, generally 
associated with inhibition of cell proliferation (Razanajaona, Joguet et al., 2007). 
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3.5.2. K562 differentiation assay 
 
It has long been known, that activin A induces erythroid differentiation in the 
erythroleukemia cell line K562 (Schwall, Nikolics et al., 1988; Shav-Tal & Zipori, 
2002). 
This can easily be visualized and quantified by staining the cells with 
3,3’-dimethoxybenzidine for hemoglobin which accumulates as a consequence of 
differentiation. For that reason, the assay is frequently used to determine influences 
on activin A signaling (Lebrun & Vale, 1997; Wang, Huang et al., 2008). 
In a first test of the assay outlined in the methods section, we could show that 
treatment with hemin (50 μM), suggested by Zhang et al. (Zhang, Cho et al., 2007), 
resulted in a tenfold increase in the number of cells stained positive with benzidine, 
while treatment with activin A (25 ng/mL) resulted in a threefold increase after five 
days in culture (see Figure 25). The latter is in accordance with the induction 
suggested by Wang et al. (Wang, Huang et al., 2008), while for hemin significantly 
higher numbers have been reported (Nagai, Shimizu et al., 2007). 
 
 
Figure 25 percentage of benzidine positive cells after treatment with hemin or activin A 
K562 cells were seeded at a density of 50 000 cells per 24-well into RPMI medium with 10% FBS or 
RPMI 10% FBS with 50 μM hemin or RPMI 10% FBS with 25 ng/mL activin A; after 5 days, cells were 
stained for hemoglobin 
 
We then went on to test if supernatants of cells expressing different variants of 
activin beta E would also cause differentiation of K562 cells, or else influence the 
effects caused by activin A. To test this, K562 cells were incubated with conditioned 
media from virus transduced HepG2 cells (at that time, it was not known that in 
many, but not all cases, supernatant from virus transduced HepG2 cells would only 
contain biologically inactive activin A – see 3.5.3.1) or supernatant from CHO cell 
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lines. Since we found that incubating K562 cells with serum free medium resulted in 
the death of the majority of the cells, serum free HepG2 supernatants were diluted 
1:2 with MNP medium with 10% FBS while the supernatant from CHO cells contained 
10% FBS from the beginning. A summary of the results is shown in Figure 26. 
 
 
 
 
Figure 26 effect of activin E containing supernatants produced in HepG2 cells and CHO 
cells on the differentiation of K562 cells 
top: K562 cells were incubated with conditioned media from virus transduced HepG2 cells either 
expressing activin beta A (cmG2 AßA) or activin beta E – HA (cmG2 AßE-HA); recombinant activin A 
(rh ActA) served as a positive control; 
bottom: K562 cells were incubated with conditioned media from CHO cell lines either mock 
transfected (cmC mock), or expressing different variants of activin beta E (cmC AßE; cmC AßE-HA; 
cmC AßE-GFP); to test for an interplay, recombinant activin A was added to the cell supernatants; 
fresh CHO medium (MEMa) served as control; FLRG was added as control for the inhibition of 
activin A; see text for details;  staining was performed after 4 days of incubation in both experiments 
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Although treatment with activin A consistently resulted in an induction of 
differentiation of K562 cells, the effect caused by small amounts of activin A (for 
example 5 ng/mL) was rather mild and often almost within the margin of error. 
Cotreatment with FLRG inhibited the effect of activin A, while activin E variants by 
themselves had no effect on K562 cells. There was no clear evidence that 
cotreatment of K562 cells with activin E and activin A would influence the effects of 
the latter significantly. Only in case of HA-tagged activin E (expressed by the CHO 
cell line CHO-D46) cotreatment seems to increase the effect of activin A (in 
comparison to supernatant of the mock transfected CHO cell line CHO-A71, cmC 
mock). See discussion for details. 
Despite the problem with the expression system, activin A produced by baculovirus 
infected HepG2 cells potently induced differentiation of K562 cells. 
 
 
3.5.3.  Effects of activins on the phosphorylation status of 
mediators of signaling 
3.5.3.1. Smad 2/3 
 
It has previously been shown, that incubation of HepG2 cells with activin A results in 
phosphorylation of smad 2 which can easily be detected by western blotting of whole 
cell lysate using commercially available antibodies (Razanajaona, Joguet et al., 
2007). We used the same approach to determine if incubating HepG2 cells with 
activin E would also result in phosphorylation of smad 2, or else influence the 
activation of the smad signaling cascade by activin A. 
We found that even minimal amounts of activin A (down to 0.5 ng/mL in medium; 
data not shown) resulted in significant phosphorylation of smad 2 after 30 min that 
could be prevented by adding excess amounts of FLRG to the medium (see Figure 27 
and Figure 28 respectively). 
 
Results  62 
 
Figure 27 effect of activin A on the phosphorylation status of smad 2 (left) in HepG2 cells 
and inhibition by HepG2 supernatant; total smad 2/3 (right) 
HepG2 cells were treated with increasing concentrations of recombinant activin A (rh Act A), diluted 
either in serum free medium or conditioned medium from mock virus transduced HepG2 cells 
(cmG2 mock) 
 
Treating HepG2 cells with supernatants from other HepG2 cells that had been 
infected with a baculovirus containing an expression cassette for activin A 
(baculovirus G9) unfortunately gave varying results. Supernatants from G9 infected 
HepG2 cells induced phosphorylation of smad 2 in some instances while in others 
they did not (data not shown). HepG2 cells had been chosen as targets for the 
infection with baculovirus, as they had previously been shown to be particularly 
suitable for virus mediated expression of a transgene (Boyce & Bucher, 1996). This 
unexpected observation could be explained by treating HepG2 cells with recombinant 
activin A and supernatants of mock transfected HepG2 cells at the same time. It 
could be shown that the supernatant of HepG2 cells was able to block the activity of 
up to 25 ng/mL activin A (Figure 27). Supernatant from the reporter HepG2 cells 
themselves did not interfere with activation of signaling as it was removed and the 
cells were washed directly before the addition of activin A and / or activin containing 
media (all serum free; see materials and methods). 
One possible explanation would be the binding of activin A to alpha 2-macroglobulin 
produced by HepG2 cells. Alpha 2-macroglobulin has long been known as a binding 
partner of activin A (Vaughan & Vale, 1993) and has been shown to inhibit binding of 
TGF-beta to its receptor (Arandjelovic, Freed et al., 2003). While it has been 
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suggested to aid in clearance of activin A (Niemuller, Randall et al., 1995), other 
reports have questioned its ability to inhibit biological functions of activin A (Mather, 
1996).  
Alpha 2-macroglobulin seems to be a particularly likely candidate as it is very 
abundant in the secretome of HepG2 cells (Christopher Gerner, personal 
communication). 
Another explanation would be the presence of the activin antagonist follistatin which 
has been found to be expressed by untreated HepG2 cells by some (Rossmanith, 
Chabicovsky et al., 2002) but not other groups (Bartholin, Maguer-Satta et al., 2002). 
The other important antagonist of activin A, FLRG, is not expressed significantly by 
unstimulated HepG2 cells (Razanajaona, Joguet et al., 2007). 
The problem could be overcome by changing the expression system from HepG2 
cells to MGC cells, a cell line that has recently been shown to be easily transduced 
with baculovirus (Lackner, Genta et al., 2008).  
Treating HepG2 cells with supernatants from MGC cells infected with baculovirus for 
expression of activin beta A (G9), but not treatment with supernatants of MGC cells 
transduced with a mock virus potently activated the smad 2 pathway (Figure 28). 
 
 
Figure 28 phosphorylation of smad 2 in HepG2 cells by activin A produced in MGC cells 
(left), total smad 2/3 (right) 
HepG2 cells were treated with recombinant activin A (rh ActA), with and without FLRG, or with the 
supernatants of virus transduced MGC cells expressing either activin beta A (cmM AßA) or a mock 
construct (cmM MGC) 
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Once a suitable expression system had been identified, that on the one hand was 
able to process activins correctly (as shown by production of biologically active 
activin A) and on the other hand did not interfere significantly with activin A signaling 
on its own, we went on to determined the effects of artificially expressed activin E on 
smad 2 protein. It was particularly important to have access to a well tested system 
for the transient (virus induced) expression of activins, as it was not possible to test 
if the CHO expression system used would produce cell supernatant containing 
biologically active activins. As noted before, neither could a stable cell line producing 
activin A be created, nor could the wildtype activin E be visualized. 
In our experiments, we used both supernatants of CHO cells stably expressing 
different variants of activin beta E, and MGC cells transduced with baculoviruses 
containing expression cassettes for these proteins. In both cases we found, that 
treatment of HepG2 cells with activin E (with or without a tag) did not cause 
detectable smad 2 phosphorylation (see Figure 29 and Figure 30). In addition we 
tested supernatant from HEK293 cells transiently transfected with the D32 vector or 
D41 vector. The results (not shown) were similar to those for virus transduced and 
stable cell lines. 
As activin E did not cause a detectable phospho-smad 2 signal, we investigated if 
preincubating HepG2 cells for 30 min with the supernatants of CHO cell lines (Figure 
29) or virus transduced MGC cells (Figure 30) before the addition of recombinant 
activin A would alter the signal. This was of particular interest as it has been 
suggested that the closely related activin C might act as a competitive inhibitor to 
activin A (Muenster, Harrison et al., 2005). 
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Figure 29 effect of activin E from CHO cells on smad 2 phosphorylation by activin A 
treatment (left); total smad 2/3 (right) 
HepG2 cells were incubated with fresh medium, or conditioned media from CHO cell lines, expressing 
either a mock construct (cmC mock) or different variants of activin beta E (cmC AßE; cmC AßE-HA; 
cmC AßE-GFP) for 30 min, before recombinant activin A (rh Act A) was added; addition of FLRG 
served as a positive control for the inhibition of activin A signaling; an additional 30 min later, cells 
were harvested and lysed and subjected to gel electrophoresis and western blotting using antibodies 
against phospho-smad 2 and total smad 2/3 
 
 
Figure 30 effect of activin E from MGC cells on smad 2 phosphorylation by activin A 
treatment (left); total smad 2/3 (right) 
HepG2 cells were incubated with conditioned media from MGC cells transduced either with a virus 
containing a mock expression cassette (cmM mock) or an expression cassette for activin beta E – HA 
(cmM AßE-HA); 30 min later, some of the wells were treated with recombinant activin A (rh Act A); an 
additional 30 min later, cells were harvested and lysed and subjected to gel electrophoresis and 
western blotting using antibodies against phospho-smad 2 and total smad 2/3 
 
In Figure 29 it can clearly be seen that neither any of the activin E variants 
expressed by CHO cells, nor supernatant from mock transfected CHO cells alone has 
any major effect on the phospho-smad signal caused by as little as 1 ng/mL of 
activin A. As mentioned before, there is also no evidence for a signal caused by 
activin E variants alone. 
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In case of the HA-tagged variant of activin E expressed in MGC cells, a light 
reduction in signal intensity in comparison to treatment with the supernatant of mock 
transduced MGC cells can be seen. Taking in consideration however, that 
supernatant of mock transduced MGC cells alone already causes a decrease in signal 
intensity, it cannot be ruled out that the additional decrease in case of 
activin beta E – HA expressing cells is merely caused by differences in the cell 
number and / or protein synthesis of the cells used for activin expression. Even if 
that is not the case, the effect of activin E on activin A signaling through smads has 
to be considered minor at best, judging from the data presented here. 
 
3.5.3.2. Smad 1/5 
 
As it has previously been shown that treatment of responsive cells with the closely 
related bone morphogenetic proteins (BMPs) or TGF-beta leads to phosphorylation of 
the smad proteins 1, 5 and 8 (Lee, Ray et al., 2008; Yu, Deng et al., 2008), we went 
on to investigate if activin E would act in a similar manner. The idea was further 
supported by the report of experiments in which part of the sequence of 
activin beta A was replaced with the corresponding regions from BMP-2. This 
chimerical protein no longer activated the smad 2 signaling pathway but instead 
caused phosphorylation of smad 1 (Korupolu, Muenster et al., 2008). 
Since treatment of the cell line HT1080 (suggested as positive control by the supplier 
of the antibody raised against phospho-smad 1/5) with purified recombinant BMP-2 
(Peprotech EC) did not cause any detectable phospho-smad signal, we went on to 
use HCT116 cells as reporters (Beck, Jung et al., 2006). Figure 31 shows the 
phosphorylation status of smad 1 and / or smad 5 in response to treatment with 
recombinant BMP-2 and supernatant from HEK293 cells transiently transfected with 
expression vectors for a mock construct protein (EGFP), activin beta E or 
activin beta A. Before the experiment, the cells had been starved in medium without 
serum for 1 day. Despite this, a band of similar intensity could be detected in all 
samples probed with antibody against phospho-smads 1 and 5. As it was not possible 
to see a difference even between negative and positive control (medium without 
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serum and BMP-2 respectively), determination of the effects of activin E on the 
phosphorylation of the smad proteins 1 or 5 has to await optimization of the assay. 
 
 
Figure 31 phosphorylation of smad 1/5 (left), total smad 5 (right) from HCT116 cells 
HCT116 cells were incubated either with serum free medium, serum free medium with recombinant 
BMP-2 (rh BMP-2), medium with 10% FBS, or conditioned medium from HEK293 cells transiently 
transfected with a  mock expression vector (cm293 mock), an expression vector for activin beta E 
(cm293 AßE) or an expression vector for activin beta A (AßA) for 30 min; cells were then harvested 
and lysed and subjected to gel electrophoresis and western blotting using antibodies against 
phospho-smad 1/5 and total smad 5 
 
3.5.3.3. MAP kinases and S6 protein 
 
In the course of investigating the effects of activins on the phosphorylation status of 
smad 2 in HepG2 cells, we also assessed the phosphorylation of ERK 1 and ERK 2 as 
well as ribosomal protein S6. No difference could be seen between different samples 
in case of S6 protein (not shown), probably caused by the experimental setup which 
did not include starving (Sonvilla, Allerstorfer et al., 2008). In case of ERK 1/2 
phosphorylation, the results were very inconsistent (not shown), which is likely to 
have been caused by the different kinetics of ERK and smad phosphorylation 
(Dupont, McNeilly et al., 2003), and the fact that the experiment had been optimized 
for the investigation of smad signaling. 
 
 
 
Results  68 
3.5.4. Receptor internalization 
 
One approach to identify a possible receptor for activin E was the visualization of 
receptor-internalization in response to treatment with the ligand. To do so, members 
of the lab of Michael Grusch had created chimeras between various receptors for 
members of the TGF-beta family, and fluorescent proteins. A similar approach had 
previously been described for the receptor of epidermal growth factor (EGF) (Carter 
& Sorkin, 1998). 
Transfection of HEK293 and CHO cells with one or several of the constructs resulted 
in the expression of fluorescent proteins correctly localized to the membrane in only 
a tiny fraction of the cells. Most of the cells expressing the constructs reacted by 
apoptosis a few days after transfection.  Similar observations have been made by 
other groups (Chen, Woodruff et al., 2000).  
In preliminary experiments, HEK293 and CHO cells transfected with an expression 
vector for an EGF-receptor-EGFP chimera failed to react by visible internalization of 
the membrane protein following treatment with recombinant EGF (20 ng/mL; 
Peprotech EC) – see Figure 32. While in HEK293 cells, this may be attributed to the 
reported very low capacity of the endocytotic machinery of these cells (Carter & 
Sorkin, 1998), the reason for a lack of internalization in CHO cells remains unknown 
as the process has been shown to work efficiently in this cell line (Szymkiewicz, 
Kowanetz et al., 2002). 
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Figure 32 HEK293 (top) and CHO cells (bottom) expressing an EGFP tagged EGF receptor, 
1 (left) 45 (middle) and 90 minutes (right) after stimulation with recombinant EGF 
(20 ng/mL)) 
 
Despite the toxicity of the product, it was possible to create cell lines stably 
expressing BMP receptor 1B - EYFP and activin receptor 2B – ECFP by subcloning or 
FACS sorting. These may be used in future experiments for the co-precipitation and 
identification of a bound ligand (Harrison, Gray et al., 2004; Lebrun & Vale, 1997; 
van der Wijk, Blanchetot et al., 2005). 
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4. Discussion 
 
4.1. Expression of activin beta E and its tagged variants 
 
The results presented in this thesis suggest that, the CHO expression system and the 
BacMam viral expression system work well for the biosynthesis of activins. Especially 
the production of bioactive activin A proves that the viral expression system should 
also be able to produce activin E that has (at least in parts) been correctly processed.  
Previous reports of the synthesis of bioactive activin A by CHO cells (Arai, Tsuchida 
et al., 2006; Wada, Maeshima et al., 2004) make it appear likely that our CHO 
expression system is also capable of producing functional activin E. 
The absence of a CHO cell line expressing activin beta A and the unclear results from 
gel electrophoresis of activin E containing supernatants under non-reducing 
conditions however made final validation of the suitability of this expression system 
impossible so far. 
In general it was found that the resolubilization of EtOH precipitated proteins is not 
an easy task. Even in sample buffer containing 8 M urea, a large portion of the 
precipitate would not go into solution. Even when it did, some of the protein seemed 
to remain in large aggregates. This was for example seen in case of precipitated 
DsRed protein which migrated in a band of intense pink above 100 kDa despite the 
presence of a strong denaturing agent, DTT and 2-mercaptoethanol in the sample. 
This property of DsRed has been described before for non-reducing gel 
electrophoresis (Baird, Zacharias et al., 2000). It may well be, that this problem can 
be overcome by the use of different precipitation techniques and / or optimizations. 
Using different techniques for the enrichment of activin E in the sample, like classical 
chromatographical methods used for the purification of activin A (Smith, Yaqoob et 
al., 1988) or affinity purification used in case of different activin chimeras (Korupolu, 
Muenster et al., 2008; Muenster, Harrison et al., 2005) would probably avoid this 
altogether. Early attempts at the latter showed that this approach could in principal 
be successfully applied to HA-tagged (and GFP-tagged) activin E but also required 
optimization. 
It has to be noted however, that while the CHO expression system could not be 
validated to 100% so far, data obtained by the use of conditioned media from 
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transiently transfected and virally transduced cell lines which were shown to be able 
to express and process activins successfully (HEK293 and MGC respectively) was 
similar to results from experiments with CHO cell lines. 
The ability of the Sf9 expression system to produce correctly processed activin E – 
although previously shown for activin A (Wuytens, Verschueren et al., 1999) – 
remains to be tested. An early western blot (not shown) however indicated that the 
cells were able to produce large amounts of HA tagged protein that also tended to 
form different aggregates. 
We and others (Antenos, Stemler et al., 2007; Arai, Tsuchida et al., 2006; 
Hashimoto, Ushiro et al., 2006; Mellor, Cranfield et al., 2000; Ushiro, Hashimoto et 
al., 2006) also identified prominent high molecular weight bands (though with 
varying intensities in comparison to the mature peptide) corresponding to the 
proform of the respective protein subunits in the supernatants of different cells 
ectopically expressing different activins. If the large portion of proform activin beta E, 
especially in the CHO system is caused by the reported low levels of the 
(prospective) converting enzyme furin (Ayoubi, Meulemans et al., 1996) remains 
unknown. Co-expression of furin / SPC1 or SPC 5 or 7 together with activin beta E –
 HA in CHO cells however did not noticeably shift the balance away from the proform 
towards the mature peptide (not shown).  
 
4.2. Biological properties of activin E 
 
A basic evaluation of the growth characteristics of CHO cell lines stably expressing 
activin beta E or tagged variants pointed towards an anti-proliferative effect of the 
protein in the expressing cell. This is in general accordance with observations made 
previously (Chabicovsky, Herkner et al., 2003; Vejda, Erlach et al., 2003). It has to 
be noted however, that this might at least in part be due to the stress upon the ER 
of cells highly overexpressing this secreted protein. A comparison with cell lines 
overexpressing other secreted proteins or even a biologically inactive variant of 
activin A (Fischer, Park et al., 2003; Wuytens, Verschueren et al., 1999) could help 
answering this question.  
Treatment of the hepatoma cell lines HepG2 and Hep3B with activin E containing 
media however showed no strong inhibition of the proliferation of these cells as it 
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had been reported for activin A (Chen, Woodruff et al., 2000; Razanajaona, Joguet et 
al., 2007). This fits well with the observations made in K562 differentiation- and 
smad phosphorylation assays. 
As already mentioned in the results section, the determination of the effects of 
activins on K562 cells was rather difficult. This was mainly due to the high variability 
of the results. The fact that conditioned media rather than purified activin E had to 
be used for these long term experiments was definitely one of the causes of this. On 
the one hand did the supernatants quite certainly contain rather different 
concentrations of the protein of interest as well as additional factors secreted 
and / or released by the producer cell lines. On the other hand did activin beta E 
producing- and mock transfected cell lines have a different consumption of their 
growth medium and growth factors from the serum due to highly different 
proliferation rates. This could already be told from the fairly different color of the 
supernatants from different cell lines. While it would be possible to overcome this 
particular problem by dialysis of cell supernatant against fresh medium, the presence 
of different amounts of other proteins that might have an effect on K562 cells 
(especially given the long incubation time), could only be avoided by purification of 
activin E. 
Nonetheless, there is no evidence that secreted activin E alone has any major effect 
on the differentiation of K562 cells toward the erythroid lineage. 
Similar results were found for the related activin C which did not cause activation of 
activin A responsive elements in reporter gene assays (Mellor, Ball et al., 2003). As it 
has been suggested that this protein might act as competitor of activin A for the 
binding to the receptor ActRII (Muenster, Harrison et al., 2005), we performed the 
co-incubation experiments described in the results section. 
Results from cotreatment of the erythroleukemia cells with activin A and activin E 
however were less clear than results from treatment of the cells with one or the 
other protein alone. This was especially the case, as incubation of K562 cells with 
activin A in the supernatant of mock transfected cells had only a minor effect, while 
incubation with the supernatant activin beta E – HA expressing cells and activin A 
caused a major induction of differentiation. One could speculate that this effect is 
caused by the depletion through activin E of some inhibitor of activin A produced by 
CHO cells (see below). The concerns mentioned above however, apply particularly 
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well to the mock transfected CHO cell line and the CHO cell line producing 
activin beta E – HA (compare for example light microscopy images of the cells – 
Figure 13). Although this would in theory be supported by data presented in Figure 
29, the large margin of error of the K562 assay and the lack of support for this 
observation by treatment with supernatant from MGC-G12 cells (transduced with a 
virus containing the same expression cassette) in the smad assay makes this 
conclusion rather doubtful. The fact that activin A exerts its function in the 
differentiation of erythroid cells via signaling through serine / threonine 
transmembrane receptors and smad proteins (Shav-Tal & Zipori, 2002), and that 
inhibition of this pathway also inhibits the effects of activin A (Lebrun & Vale, 1997; 
Wang, Huang et al., 2008), supports the assumption that assaying the pathway 
further upstream, namely at the level of receptor smad phosphorylation, should yield 
the same information as observing the degree of differentiation of K562 cells. 
 
While we could show that both recombinant activin A and the supernatant from cells 
expressing activin beta A induce phosphorylation of smad 2 protein in HepG2 cells, 
supernatants of activin beta E (tagged and untagged) producing cells had no such 
effect. Since this result was repeatedly shown with conditioned media from several 
expression systems (baculovirus transduced HepG2 and MGC cells, stable CHO cell 
lines and transiently transfected HEK293 cells) which were all in principle able to 
produce bioactive activin A, it can be considered quite reliable. This is especially the 
case due to the high sensitivity of the system (0.5 ng/mL of recombinant activin A 
resulted in a clear phospho-smad signal) and good reproducibility of the results. It 
cannot be ruled out however, that activin E might need other receptors or additional 
coreceptors no present in either K562 or HepG2 cells for smad activation. 
In cotreatment experiments, there was no strong difference in the phosphorylation of 
smad 2 protein after treatment with activin A diluted in supernatants from mock 
transfected or activin beta E expressing cell lines. While the assay would certainly not 
be able to detect very subtle effects of activin E on activin A signaling, it can be 
expected that the affinity of activin E for (one of) the receptors responsible for 
binding and signaling of activin A is rather low, if significant at all. Since the 
concentration of activin A in the medium (1 ng/mL) was close to the minimum 
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required for detectable phosphorylation, one would expect that addition of significant 
amounts of a competitive inhibitors would abolish the signal altogether. 
Of course this can only be a raw estimation based on the results presented here. 
Final testing of the affinity of activin E for receptors of activin A (for example by 
measuring the displacement of radio-labeled activin A (Muenster, Harrison et al., 
2005) has to await successful purification and quantification of activin E. Despite this, 
neither assaying the phosphorylation of smad 2 proteins, nor determining the 
differentiation of K562 cells gave any indication for a direct inhibition of activin A 
signaling by activin E. 
Induction of phosphorylation of smad 1 and / or smad 5 by activin E could not be 
thoroughly tested. Although these smads have previously been associated with the 
BMP branch of the TGF-beta family, it has been shown that even TGF-beta itself can 
activate this subset of signal mediators depending on the cell type (Schmierer & Hill, 
2007). A repetition of the experiment however should help answer this question. 
 
4.3. Identification of a receptor binding Activin E 
 
The most straight forward way to answer which – if any – of the known TGF-beta 
family receptors binds activin E of course would be immunoprecipitation of ligand 
receptor complexes. The stability of which could be significantly enhanced by 
covalent crosslinking (Lebrun & Vale, 1997). Two approaches are generally possible. 
CFP / YFP tagged receptors could be precipitated following incubation with activin E 
and then be analyzed for the coprecipitation of the ligand by western blotting 
(Lebrun & Vale, 1997; Wuytens, Verschueren et al., 1999). Alternatively, lysate of 
cells that have been treated with activin E could be incubated with antibodies / beads 
directed at the ligand or its tag. Interaction partners could either be detected using a 
candidate approach (for each experiment, cells would be transfected with one of the 
TGF-beta family receptors fused to tag) or by mass spectrometry (Cheeseman & 
Desai, 2005; Steen & Mann, 2004). The advantage of precipitating the ligand would 
be that all purified protein has indeed bound to an interaction partner on the cell as 
unbound activin E would be washed away before crosslinking and precipitation. This 
would allow precipitating protein from a very large number of cells making detection 
of a signal more likely.  
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Such an experiment is currently hindered however by a lack of tools to be used as 
controls. The main problem is that by the time the experiments for this thesis were 
finished, no HA-tagged activin A was available. Since it is currently only possible to 
detect and / or pulldown tagged activin E, it would first be essential to show that the 
presence of this tag does not automatically render the protein inactive or alter its 
receptor specificity. Secondly, it would be important to show that HA-tagged activin 
can be used either to co-precipitate its receptor or be detected following pulldown of 
the receptor. 
In a preliminary experiment, K562 cells were incubated with activin E – HA, washed, 
and treated with the membrane impermeable crosslinker DTSSP (DiMartino & Kew, 
1999). This was followed by pulldown using anti-HA-agarose beads. In a western 
blot using rat-anti-HA antibody, no clear difference could be seen between the band 
pattern (most likely caused by eluted antibody from the beads) from negative control 
(pulldown from K562 lysate that had not been incubated with HA-tagged activin E) 
and from activin E - HA treated K562 cells (not shown). As no positive control could 
be used however, this negative result can be seen as a little hint at best. 
Another option would be the visualization of binding (and internalization) of activin E 
to whole cells. While this approach would not allow for the identification of a binding 
partner, it is probably much simpler to perform than a pulldown. In a similar 
experiment it has been shown that bound, labeled activin A can be visualized by 
histological approaches on whole cells (Jullien & Gurdon, 2005). If this could be 
shown in a similar manner for activin E, it would be an important step forward. Again 
however this would require either tagged activin A (HA or EGFP) as a positive 
control, or “pure” activin E that could be labeled by other means. 
As it has been shown, that activin A causes internalization of its receptor ActRIIB 
(Zhou, Scolavino et al., 2004), it should also be possible to visualize this process 
using tagged versions of the receptor (Jullien & Gurdon, 2005). By one-by-one 
testing of possible receptors for activin E for internalization following incubation with 
the latter, it might be possible to identify the binding partner of this protein. The 
advantage of this approach would be that it could also be performed using 
conditioned media from cells expressing untagged activin E and (for a positive 
control) untagged activin A. However, it has already been mentioned in the results 
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section that early attempts at this assay failed and that a significant degree of 
optimization might be necessary. 
 
4.4. Other important effects of activin beta E expression 
 
One important question that could not be addressed at all during the course of this 
diploma thesis was the formation of activin heterodimers containing the beta E 
subunit. Using a 2D gel electrophoresis approach, the formation of activin AE and 
activin CE has previously been shown (Vejda, Cranfield et al., 2002). It has been also 
suggested that heterodimers between activin beta A and activin beta C have 
distinctly different properties than homodimers of activin beta A. This could be one 
way of regulating activin A activity (Mellor, Ball et al., 2003). By transducing cells 
with the two baculoviruses expressing activin beta A and activin beta E – HA 
described in the results section, followed by pulldown using anti-HA-agarose beads, it 
should be possible to test activin AE. Assuming that heterodimers can be purified this 
way, in a next step, their biological properties in comparison to those of activin A 
could be determined. Again the main prerequisite for this would be the availability of 
biologically active activin beta A – HA which would serve as a proof that the 
purification procedure does not render the protein inactive. As an alternative, 
classical biochemical methods could be used to purify activin heterodimers containing 
the beta E subunit (Pangas & Woodruff, 2002). This however could only be done in 
cooperation with a group routinely employing these techniques. 
Finally it would be important to know if, and (roughly) with what affinity activin E (or 
activin beta E containing activins) binds to known antagonists of activin A. 
While Hashimoto et al. (Hashimoto, Tsuchida et al., 2002) showed an interaction 
between activin E and follistatin, no evidence for binding of activin E to 
follistatin-like 3 / FLRG has been published so far. We and others show 
(Razanajaona, Joguet et al., 2007) that FLRG inhibits smad phosphorylation after 
treatment with activin A. A simple competition experiment with smad 
phosphorylation as readout should easily tell if activin E relieves its more famous 
relative from repression by its antagonists via binding to the latter and by this 
inactivating them. Such a mechanism would be most relevant in tissues like the liver, 
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where activin beta E, beta A and its antagonists are co-expressed and where the 
expression level of activin beta E by far exceeds that of activin beta A. 
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5. List of abbreviations 
 
ActR – activin receptor 
ACVR – activin receptor 
ALK – activin receptor–like kinase 
APS – ammonium persulfate 
BMP – bone morphogenetic protein 
BSA – bovine serum albumin 
CFP – cyan fluorescent protein 
CIAP – calf intestinal alkaline phosphatase 
cm293 – conditioned medium from HEK293 cells 
cmC – conditioned medium from CHO cells 
cmG2 – conditioned medium from HepG2 cells 
cmM – conditioned medium from MGC cells 
DHFR – dihydrofolate reductase 
DMSO – dimethyl sulfoxide 
DTSSP – 3,3´-dithiobis[sulfosuccinimidylpropionate] 
DTT – dithiothreitol 
EDTA – ethylenediaminetetraacetic acid 
EGF – epidermal growth factor 
EtOH – ethanol 
FBS – fetal bovine serum 
FLRG – follistatin–related gene 
GFP / EGFP – green fluorescent protein / enhanced green fluorescent protein 
GOI – gene of interest 
HA – hemagglutinin 
HT – hypoxanthine 
IHC – immunohistochemistry 
IPTG – sopropyl β–D–1–thiogalactopyranoside 
IRES – internal ribosome entry site 
LB – lysogeny broth (aka luria broth)2 
MAP kinase – mitogen–activated protein (MAP) kinase 
MeOH – methanol 
MOI – multiplicity of infection 
MTX – methotrexate 
o/n – overnight 
P/S – penicillin, streptomycin 
                                                 
2 Bertani, G. (2004). Lysogeny at mid-twentieth century: P1, P2, and other experimental systems. J 
Bacteriol, 186, 595-600. 
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PBS – phosphate buffered saline 
PFA – paraformaldehyde 
Pfu – plaque forming units 
PNK – T4 polynucleotide kinase 
PVDF – polyvinylidene fluoride 
rh Act A – recombinant human activin A 
RT – room temperature 
SDS – sodium dodecyl sulfate 
SDS–PAGE – sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SOB – super optimal broth 
SOC – SOB with “B” changed to “C” for catabolite repression because of added glucose 
STET – sodium chloride Tris EDTA Triton X–100 buffer solution 
T/E – trypsin/EDTA 
TBE – Tris/borate/EDTA 
TBS – Tris buffered saline 
TCA – trichloroacetic acid 
TE – Tris EDTA buffer solution 
TEMED – N,N,N’,N’–tetramethylethylenediamine 
TGF–beta – transforming growth factor beta 
Tris – tris(hydroxymethyl)aminomethane 
X–gal – 5–bromo–4–chloro–3–indolyl beta–D–galactopyranoside 
YFP – yellow fluorescent protein 
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